Each month,TheClinical Advisormakes one new clinical feature available ahead of print. Dont forget to take the poll. The results will be published in the next months issue.

Major depressive disorder (MDD) is a common mental disorder that affects more than 264 million people worldwide and is a leading cause of disability, including death by suicide.1 MDD is a complicated disorder that involves the interaction of social, psychological, and biological factors.1 MDD can prevent patients from living healthy, productive lives and can complicate treatment of other comorbid conditions.1

Although MDD commonly is encountered in primary care settings, its treatment has become integrated into all fields of medicine due to its high prevalence. Cognitive behavioral therapy, interpersonal psychotherapy, and antidepressants, such as selective serotonin reuptake inhibitors and tricyclic antidepressants, are the mainstays of MDD treatment.1

Prescribing an antidepressant may be simple, but that does not make it easy. Efficacy and tolerability of antidepressants vary among patients, which can make it challenging to relieve patients symptoms.2 Although no genes have been associated with depression,3 several genetic variants may help clinicians predict how patients with MDD will metabolize antidepressants.4 Performing genetic testing of patients with MDD and matching patients with an antidepressant class based on identification of genetic variants that convey sensitivity to particular antidepressants could improve response to drug therapy in patients with MDD.5

The process of selecting an antidepressant should take into account cost, tolerability, adverse effect profiles, and patient preferences.2 When evaluating treatment options for patients with MDD, the current standard of care is to initiate an antidepressant at a starting dose and reassess effectiveness within 2 to 4 weeks, with adjustments to monitoring frequency dependent on the patients suicide and self-harm risk, comorbid conditions, age, and concomitant medication use.2

Several metrics are used to determine whether a selected antidepressant is working:

Clinicians can mitigate adverse effects by decreasing the dosage or switching to a different class of antidepressant. However, several weeks are needed after each change in drug or dose alteration to truly assess response. Finding and settling on a drug that produces a response with minimal adverse effects can take months. During the trial period, patients may become frustrated with the process and stop therapy and/or may be at increased risk for suicide or self-harm.

The study of drug metabolism in patients with MDD is a growing area of interest.3-5 A management approach incorporating pharmacogenetic testing in combination with clinical judgment may be superior to the standard trial and error method for finding an effective antidepressant regimen and could improve patient outcomes.5

Genome-wide association studies are used to identify single nucleotide polymorphisms (SNPs) in genes related to a particular disease or drug metabolism.6 Several laboratory testing companies offer pharmacogenetic panels to evaluate metabolism of drugs used to treat MDD.3 The FDA also has approved direct-to-consumer genetic testing panels (eg, 23andMe), which are widely available to the public without a health care providers prescription.7 A concern with these latter tests is that the results of these tests are reported directly from the company to the patient; thus, the patient decides whether or not to present the information to his or her health care provider. Many pharmacogenetic testing panels also include genes that have shown correlations with the pathogenesis of MDD, despite the lack of clinical research replicating the role of these genes in the disorder.3

From the October 2020 Issue of Clinical Advisor

Originally posted here:
Pharmacogenetic Testing: Does it Improve Therapy in Patients With MDD? - Clinical Advisor

Recommendation and review posted by Bethany Smith

Eczema (a.k.a. atopic dermatitis) isnt rarein fact, the National Eczema Association reports that over 31 million Americans are currently living with the skin condition. Though it usually begins in childhood, eczema can crop up at any time, causing itchy, dry skin that comes and goes in flares. Its more severe in some people than others, but one thing is certain: Its not exactly a walk in the park to deal with.

But now, scientific breakthroughs are revealing more about the genetic origins of eczema. An August 2020 study in Nature Communications found that two common mutations of the KIF3A gene are responsible for an impaired skin barrier, which can contribute to the development and onset of atopic dermatitis. KIF3A is a gene that we found to be very important in determining skin barrier function in people, says Gurjit Neeru Khurana Hershey, M.D., director of the Division of Asthma Research at Cincinnati Children's Hospital in Cincinnati, OH, and principal investigator on the study. Individuals that carry common genetic variants in this gene had disrupted skin barrier function as evidenced by increased loss of water through their skin. This promotes skin dehydration, which increases the odds that someone will start feeling that dreaded eczema itch.

Heres why this genetic discovery is so huge: Identifying these genes early on could help doctors identify children at risk of developing eczema and a whole host of related health problems like asthma and allergies later in life.

The cause of eczema isnt totally clear, but scientists know it has something to do with both nurture (external factors) and nature (family history). Research in the Expert Review of Clinical Immunology found evidence for several environmental risk factors, including personal care product use, air pollution, climate factors like heat and humidity, and even dietary choices.

If eczema runs in your family, your chance of getting it is significantly higher, with or without those external triggers. One possible reason: You've inherited certain genetic mutations from your parents. Jonathan Silverberg, M.D., associate professor of dermatology at The George Washington University School of Medicine and Health Sciences in Washington, D.C., notes that researchers had previously identified mutations of the Filaggrin (FLG) gene as playing a role in atopic dermatitis. The KIF3A gene (the one in this current study) was also previously associated with atopic dermatitis and allergic disease, but its role was not precisely understood.

This study has several significant findings that bridge genetic associations to potential pathomechanisms of atopic dermatitis, Dr. Silverberg saysmeaning, the ways in which eczema starts occurring in the first place.

So, now youre probably wondering OK, so what can I actually do with this information? Though it doesnt change anything right this instant, this finding could lead to better genetic testing to identify infants at high risk for eczema. And since half of people with moderate to severe eczema go on to develop asthma, hay fever, or food allergies, early detection would help doctors be on the lookout forand proactively treatthese additional health complications. I hope that testing for this genetic variation will help identify kids at risk for food allergy and asthma before they develop, so we can prevent disease onset or attenuate their disease, Dr. Hershey says.

Unfortunately, prevention is a bit complicated. Dr. Silverberg explains that researchers have tried a variety of interventions aimed at preventing or mitigating eczema, including moisturizers, prebiotics, probiotics, and avoidance of external triggers like dust mites. While individual studies showed possible benefits, none of these have conclusive evidence to support their recommendation in routine practice, he says. So, at this point, even if we could identify children at higher risk for atopic dermatitis, there isnt that much we can do about it.

Dr. Hershey hopes this new research will lead to specific treatment approaches that target the KIF3A gene. Ideally, scientists would discover a way to repair skin barrier function in infants before they have noticeable eczema symptomsthereby stopping it before it starts.

If you or a loved one lives with eczema, you know how life-changing this breakthrough could be. The psychosocial and mental health burden of atopic dermatitis can be improved tremendously simply by achieving tighter control of the signs and symptoms of atopic dermatitis, Dr. Silverberg says. This isnt the golden ticket (yet), but its one step closer to getting there.

Read more:
The Eczema Gene Thats Kind of a Big Deal - HealthCentral.com

Recommendation and review posted by Bethany Smith

FT MYERS, FL / ACCESSWIRE / September 10, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Doug Brown, Chief Strategy and Corporate Development Officer, will be participating in a virtual fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference on Monday, September 14, 2020 at 9:45am ET.

The presentation will be webcast live and accessible online via the investors section of the Company's website, http://www.neogenomics.com. A replay of the webcast will be archived for 90 days following the presentation.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad, Fresno and San Diego, California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit http://www.neogenomics.com/.

Forward Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company's ability to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, as well as additional factors discussed under the heading "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on February 28, 2020. As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. In addition, it is the Company's practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http://ir.neogenomics.com/.

Forward-looking statements represent the Company's estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Company's estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.

For further information, please contact:

NeoGenomics, Inc.

Doug BrownChief Strategy and Corporate Development OfficerT: 239.768.0600 x2539M: 704.236.2064doug.brown@neogenomics.com

Charlie EidsonManager of Investor Relations and Manager of Strategy and Corporate DevelopmentT: 239.768.0600 x2726M: 952.221.8816charlie.eidson@neogenomics.com

SOURCE: NeoGenomics, Inc.

View source version on accesswire.com: https://www.accesswire.com/605665/NeoGenomics-To-Virtually-Participate-In-Fireside-Chat-At-The-18th-Annual-Morgan-Stanley-Global-Healthcare-Conference

See the original post here:
NeoGenomics To Virtually Participate In Fireside Chat At The 18th Annual Morgan Stanley Global Healthcare Conference - Yahoo Finance

Recommendation and review posted by Bethany Smith

A Boston consumer genetics company that has batted away former employees accusations of shoddy practices since at least 2019 is now under investigation by the state Department of Public Health for logging hundreds of false positive coronavirus test results, including some in Fall River and Taunton.

The company, Orig3n, has halted COVID-19 testing in the state. A company spokesman said the false positives were due to human error in processing the tests.

In August, after learning about the Massachusetts investigation, North Carolina issued a stop order for its coronavirus testing contract with the company, Orig3n.

The consumer genetics start-up, which claims it can tell customers what kind of foods they should eat and whether theyre predisposed to intelligence based on their DNA, has secured some of the biggest coronavirus testing contracts in the country.

According to an Orig3n spokesman, the company continues to offer COVID-19 testing elsewhere in the U.S.

So far, the Massachusetts DPH has found Orig3n sent out more than 300 COVID-19 tests wrongly classified as positive in Massachusetts, a number that could increase as DPH staff continue investigating. Orig3n claims the company isnt aware of any additional false positives. According to a Harvard epidemiologist and lab director, false negatives are far more difficult to discover, because most tests come back as negative.

Ted Owens, CEO at North Hills Pines Edge skilled nursing facility in Needham, one of roughly 60 long-term care facilities that used Orig3n test services, said in an Aug. 11 bulletin to residents and staff that Orig3n returned a total of 19 false positives to the nursing home.

The numbers didnt seem credible to Owens, but Pines Edge began immediately to take actions based on the working assumption that we needed to treat these results as correct.

It turned out that several other skilled nursing facilities also showed an unusual spike in positive cases last week, and oddly enough, all these facilities had used the same testing vendor, Owens continued. This caught the attention of the epidemiologists at Mass DPH, who intervened and instructed the vendor to re-test the samples.

Upon retesting, all of the positive tests were found to be negative.

The spike in cases -- which turned out to be false positives -- caused a panic in Needham. They came as the school district made plans to return to in-person learning, and a public health nurse for the town was asked to appear before its Select Board.

Needham Public Health Nurse Tiffany Zike told the Board on Aug. 18 that a number of coronavirus cases reported in July were considered false cases that were revoked due to the lab having an issue.

A $25,000 wire transfer

In early May, nursing homes across Massachusetts were looking for a miracle.

The Massachusetts DPH had ordered long-term care facilities coping with severe coronavirus outbreaks to test 90% of residents and staff for COVID-19 by May 25 in order to qualify for a portion of the $130 million in relief funding offered by the state.

Many nursing homes struggled to meet the deadline because of a shortage of COVID-19 tests. The National Guard was testing nursing home residents and staff on behalf of the state, but demand was high.

When Ron Doty got a memo from the Massachusetts Senior Care Association on May 6 offering Orig3n as a turnkey mobile testing option, he immediately reached out to the company.

Doty, administrator at Marlborough Hills Rehabilitation & Health Care Center in Marlborough, wired $25,000 to Orig3n. The next day, he received 250 COVID-19 test kits from the company.

Two months later, Orig3n was asked to suspend COVID-19 testing in Massachusetts, which it did on Aug. 8. Staff at the Massachusetts DPH noticed the lab was reporting an unusually high rate of positive tests, prompting the agency to investigate, according to a DPH spokesperson.

The state DPH declined to identify which nursing homes used Orig3ns testing services, citing the ongoing investigation.

Tony Plohoros, Orig3ns spokesman, said the lab is now working with state health officials to correct problems in its Boston lab, which has ceased processing coronavirus samples but continues to process consumer genetic profiles.

While it remains unclear if the federal government has taken action to halt use of Orig3ns COVID-19 testing services in other parts of the country, as North Carolina did, concerns about Orig3n hadnt yet reached a health care supply company in Ohio as of this week. That company, Link-age Solutions, is still working with Orig3n to provide coronavirus tests to long-term care facilities nationwide.

Patrick Schwartz, a spokesman for Link-age Solutions, said Thursday the company was unaware Orig3n was asked to cease coronavirus testing in Massachusetts.

One of the highest accuracy ratings in the market

Orig3n received an emergency authorization to conduct COVID-19 testing from the Food & Drug Administration in April.

The same month, the company received a federal Paycheck Protection Program loan valued between $350,000 and $1 million from Silicon Valley Bank, according to U.S. Treasury data.

Since getting the FDA approval, Orig3n has provided testing services to The New England Power Generators Association, Bostons homeless population, a boarding school in Virginia, and other public and private entities.

In late June, Link-age Solutions, a Mason, Ohio-based company that helps long-term care facilities nationwide obtain supplies ranging from pharmaceuticals to office supplies issued a press release touting Orig3ns breakthrough testing method as having one of the highest accuracy ratings in the market.

In partnering with Orig3n, Link-age could offer in-demand coronavirus tests to its members at a reduced cost, according to the press release. Results would be returned less than 36 hours after specimens arrived at the lab, the release said.

The lab boasts output capabilities of 6,000 and up to 12,000 tests per day, and will offer billing to Medicare where appropriate, the press release stated. Reporters questions to the Centers for Medicare & Medicaid Services have gone unanswered.

Schwartz, the Link-age spokeman, said Thursday his company continues to offer COVID-19 testing services performed by Orig3n, and that feedback about Orig3ns tests from its customers has been positive.

Company flagged in the past

Orig3n lists its office location as the third floor of 27 Drydock Ave. in the heart of Bostons Seaport. Until August, thats where the company processed its coronavirus tests.

Before it got into the coronavirus business, Orig3n billed itself as a consumer genetics pioneer, carving a path toward a future of wellness and health through the use of diagnostics, genetics and biotechnology.

The company, founded in 2014, offers tests ranging in cost from $29 to $298 that are supposed to help people learn what kinds of food, exercise and beauty products would work best for their genetic profiles, and even whether they are genetically predisposed to so-called superhero traits including intelligence and strength, according to Bloomberg Businessweek.

A former Orig3n employee who spoke to Gannett New England reporters on the condition of anonymity because of a nondisclosure agreement with the company said the number one complaint received by customer service was genetic profile tests not being returned to customers. The employee, who left the company pre-pandemic, didnt think the company could handle both genetic profile testing and coronavirus testing.

Unless things drastically changed since I have left, not even testing, just bandwidth-wise, they were already kind of drowning when I left, the employee said.

Despite its start-up status, Orig3n quickly gained prominence partly through securing big-name partnerships, including one with the NFLs Baltimore Ravens.

In September 2017, the Ravens linked up with Orig3n for an event called DNA Day. Roughly 70,000 Ravens fans were set to pour into the teams stadium, where they could have picked up a free genetic testing kit.

The event never happened. The Ravens postponed it days before federal health officials told The Baltimore Sun they were, working to determine whether any of the testing being offered by Orig3n is subject to the requirements of the Clinical Laboratory Improvement Amendments of 1988.

The federal regulatory standards apply to labs testing human samples in the United States, and are intended to ensure accuracy, effectiveness and reliability.

About a year after DNA Day was scrapped, 17 former Orig3n employees criticized the company in Bloomberg Businessweek, alleging it, habitually cut corners, tampered with or fabricated results, and failed to meet basic scientific standards.

Marketing, not science, the employees said, was the companys priority.

Press releases put out by Orig3n throughout the pandemic show the company was eager to publicize contracts with respected institutions, both public and private.

On May 12, the company announced what it called a comprehensive solution to enable COVID-19 testing for Massachusetts nursing home residents.

In the press release, the company said it sought to become the partner of choice for coordinating and providing COVID-19 testing for defined populations beyond long-term care residents and employees, including private employers, schools, government agencies, and cities and states.

The nursing home program is one of many applications for Orig3ns fully-integrated solution, the press release said.

What went wrong?

Doty, the Marlborough nursing home administrator, would not have known about Orig3n if not for the May 6 memo from Massachusetts Senior Care Association, an organization many nursing homes relied on during the viruss spring surge in the state to interpret complex and shifting guidance from the DPH.

Massachusetts Senior Care Association President Tara Gregorio said in a statement that her organization essentially serves as a messenger for its members, and that it relies on governmental agencies to vet labs like Orig3n.

Throughout the pandemic, MSCA has passed along lists of government approved COVID-19 PCR testing labs options available to our members, Gregorio wrote. We must rely, as all providers do, on the licensing process to ensure legitimacy and accuracy of these labs.

The FDA, which gave Orig3n emergency authorization to conduct coronavirus testing last spring, has not yet responded to Gannett New England reporters seeking comment.

According to a Massachusetts DPH spokesman, Orig3n told the agency after it was contacted by DPH that errors in testing occurred because of a broken vial or contaminated plate during final processing, an explanation DPH investigators are now trying to confirm.

In an email to Gannett New England reporters on Friday, Plohoros, Orig3ns spokesman, said, human error at the beginning of the laboratory testing process caused a pre-extraction reagent that was used in the affected batch tests to become contaminated.

In an Aug. 18 press conference, Massachusetts Secretary of Health and Human Services Marylou Sudders said erroneous results from Orig3n affected the number of COVID-19 cases reported in Fall River and Taunton.

The positive test rates for that three-day period for that one lab just seemed high, and so (we) went back, and the lab stopped processing, theyre still not processing any tests, Sudders said, adding that DPH staff was analyzing tests processed prior to the discovery to make sure the issue was, as Orig3n told the DPH, a one-time problem rather than a more structural issue.

Dr. Michael Mina is an assistant professor of epidemiology at Harvard T. H. Chan School of Public Health who has experience running laboratories that perform PCR testing.

Mina says a lab that processes 6,000 to 12,000 PCR coronavirus tests a day as Orig3n has said it does would need to be run with what he called extreme quality control measures.

It requires an amazing amount of concentration and care to really ensure youre not getting contamination or any number of other problems that can happen, he said. If this was an easy (test), I would have said, sure, any lab can do it but this particular (test) ... it really is a finicky test. You have to be extremely careful about how youre doing it, and that means you need a lot of quality controls. You need to be a really diligent lab.

Mina, who stressed he has no knowledge of Orig3n other than circulating allegations that the company had previously been investigated, said when a mistake like the kind Orig3n described occurs, staff should immediately stop processing, sterilize the area and alert any affected patients and health departments.

The fact that the Massachusetts DPH noticed the problem and not Orig3n is a problem, Mina said.

That shows in general that the quality control wasnt being maintained, he said, adding that performing intense quality control checks multiple times daily is a core tenet of running any lab, especially a high-complexity clinical lab. And if were giving them the benefit of the doubt, they didnt know that there was a problem because otherwise its just nefarious.

Mina said that a professionally run lab would likely have caught the mistake, and alerted the state DPH immediately.

Part of the reason for that is simply a motive to care for the patient, who will likely make important decisions about their own behavior based on the test result they receive, which in turn affect other people.

At Brigham, for example, where I was one of the medical directors, of course people feel embarrassed (about making a mistake), but theres this strong culture where people recognize that their embarrassment is not worth a patients hardship, Mina said. Thats one thing that really, I think, lacks a little bit when we move into industry laboratories running clinical tests. That same spirit of honesty ... might not exist everywhere.

While mistakes at labs are common, Mina said, theyre also commonly fixed and they dont usually require an investigation.

Mina said that the U.S. did need to increase its capacity to process coronavirus tests this spring, but labs, especially ones new to the medical diagnostics space, as Orig3n is, need to be monitored closely.

Its just important to keep all these things in check, Mina said. The frenzy to do coronavirus testing has been so extreme. I dont think labs should be immediately shut down for mistakes, but we have to remain vigilant to ensure that all the testing that is being done is up to the highest standards.

Continued here:
Genetics start-up continues COVID-19 testing as DPH probes testing errors, including some in Fall River, Taunton - Fall River Herald News

Recommendation and review posted by Bethany Smith

The research document entitled Global Newborn and Prenatal Genetic Testing Market Growth (Status and Outlook) 2020-2025 by MarketsandResearch.biz studies and gauges through the current market forces that shows growth direction and holistic growth trends. The report acts as a thorough synopsis on the study, analysis, and estimation of the market. The report offers a concise summary of the global Newborn and Prenatal Genetic Testing market trends, end-user, regions, types, market size, revenue estimation, and geographical outlook. People seeking for their business growth on both local and global level as well as producers, newcomers in the industry, professional association, private businesses, and commercial marketers, will get a thorough assessment of the report.

Enumerating Some of The Most Important Pointers Addressed In The Report:

The report descriptively draws out the competitive backdrop of eminent players driving the market, including their product offerings and growth plans. The regional segmentation has been analyzed in terms of business opportunities, demand & supply, and revenue generation potential. The global Newborn and Prenatal Genetic Testing market distinctiveness depicted from the report is assessed to inherent and technological stance to get a better comprehension of the industry. Each geographic portion of the global Newborn and Prenatal Genetic Testing industry showcase has been freely overviewed nearby valuing, dissemination, and request information for the main geographic market.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/59725

Some well-known companies identified to operate in the global market are: Perkin Elmer, CapitalBio MedLab, Verinata Health, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Sequenom, Inc., Ariosa Diagnostics, Natera, Inc., BGI, Illumina, Inc.,

Regional segment analysis displaying regional production volume, consumption volume, revenue, and growth rate from 2020-2025 covers: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Moreover, the report highlights product launches, promotional activities, and brand tendencies, as well as ventures, acquisitions, and mergers and consolidation. The market research report classifies the competitive spectrum of this global Newborn and Prenatal Genetic Testing industry in a comprehensive manner. The raw material chain and the supply chain are described to make the user aware of the prevailing costs in the market. Our research analysts have exceptional knowledge and experience in terms of the latest market research techniques and approaches.

Segment by product type, this report focuses on consumption, market share, and growth rate of the market in each product type and can be divided into: PCR, FISH, aCGH, NIPT, MSS,

Segment by application, this report focuses on consumption, market share, and growth rate of the market in each application and can be divided into: Hospital, Clinic, Other

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/59725/global-newborn-and-prenatal-genetic-testing-market-growth-status-and-outlook-2020-2025

The Key Areas That Have Been Focused On the Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Go here to read the rest:
Global Newborn and Prenatal Genetic Testing Market Insights, Industry Top Manufactures, Analysis and Forecast 2020 to 2025 - The Market Correspondent

Recommendation and review posted by Bethany Smith

The study of Direct-To-Consumer (DTC) Genetic Testing market is a compilation of the market of Direct-To-Consumer (DTC) Genetic Testing broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Direct-To-Consumer (DTC) Genetic Testing industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Direct-To-Consumer (DTC) Genetic Testing industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Direct-To-Consumer (DTC) Genetic Testing Market report @ https://hongchunresearch.com/request-a-sample/76522

Key players in the global Direct-To-Consumer (DTC) Genetic Testing market covered in Chapter 4:,Myriad Genetics,MD Revolution,DeCODEme,23andMe,Genetrainer,GeneByGene,DNA DTC,Genecodebook Oy,Navigenics

In Chapter 11 and 13.3, on the basis of types, the Direct-To-Consumer (DTC) Genetic Testing market from 2015 to 2026 is primarily split into:,Genome Data Bank Material Model,Individual Health Planning Model,Comprehensive Genome Tests Model,Medical Precision Tests Model,Restricted Trait Tests Model

In Chapter 12 and 13.4, on the basis of applications, the Direct-To-Consumer (DTC) Genetic Testing market from 2015 to 2026 covers:,Hospital,Doctors Office,Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:,North America (Covered in Chapter 6 and 13),United States,Canada,Mexico,Europe (Covered in Chapter 7 and 13),Germany,UK,France,Italy,Spain,Russia,Others,Asia-Pacific (Covered in Chapter 8 and 13),China,Japan,South Korea,Australia,India,Southeast Asia,Others,Middle East and Africa (Covered in Chapter 9 and 13),Saudi Arabia,UAE,Egypt,Nigeria,South Africa,Others,South America (Covered in Chapter 10 and 13),Brazil,Argentina,Columbia,Chile,Others

For a global outreach, the Direct-To-Consumer (DTC) Genetic Testing study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:,Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitions,Revenue, cost price, capacity & utilizations, import/export rates and market share,Forecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Direct-To-Consumer (DTC) Genetic Testing Market Report with [emailprotected] https://hongchunresearch.com/report/direct-to-consumer-dtc-genetic-testing-market-size-2020-76522

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Direct-To-Consumer (DTC) Genetic Testing Market

Chapter Four: Players Profiles

Chapter Five: Global Direct-To-Consumer (DTC) Genetic Testing Market Analysis by Regions

Chapter Six: North America Direct-To-Consumer (DTC) Genetic Testing Market Analysis by Countries

Chapter Seven: Europe Direct-To-Consumer (DTC) Genetic Testing Market Analysis by Countries

Chapter Eight: Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Market Analysis by Countries

Chapter Nine: Middle East and Africa Direct-To-Consumer (DTC) Genetic Testing Market Analysis by Countries

Chapter Ten: South America Direct-To-Consumer (DTC) Genetic Testing Market Analysis by Countries

Chapter Eleven: Global Direct-To-Consumer (DTC) Genetic Testing Market Segment by Types

Chapter Twelve: Global Direct-To-Consumer (DTC) Genetic Testing Market Segment by Applications12.1 Global Direct-To-Consumer (DTC) Genetic Testing Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Direct-To-Consumer (DTC) Genetic Testing Sales and Market Share by Applications (2015-2020)12.1.2 Global Direct-To-Consumer (DTC) Genetic Testing Revenue and Market Share by Applications (2015-2020)12.2 Hospital Sales, Revenue and Growth Rate (2015-2020)12.3 Doctors Office Sales, Revenue and Growth Rate (2015-2020)12.4 Other Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Direct-To-Consumer (DTC) Genetic Testing Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/76522

List of tablesList of Tables and FiguresTable Global Direct-To-Consumer (DTC) Genetic Testing Market Size Growth Rate by Type (2020-2026)Figure Global Direct-To-Consumer (DTC) Genetic Testing Market Share by Type in 2019 & 2026Figure Genome Data Bank Material Model FeaturesFigure Individual Health Planning Model FeaturesFigure Comprehensive Genome Tests Model FeaturesFigure Medical Precision Tests Model FeaturesFigure Restricted Trait Tests Model FeaturesTable Global Direct-To-Consumer (DTC) Genetic Testing Market Size Growth by Application (2020-2026)Figure Global Direct-To-Consumer (DTC) Genetic Testing Market Share by Application in 2019 & 2026Figure Hospital DescriptionFigure Doctors Office DescriptionFigure Other DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Direct-To-Consumer (DTC) Genetic Testing Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Direct-To-Consumer (DTC) Genetic Testing Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Direct-To-Consumer (DTC) Genetic TestingFigure Production Process of Direct-To-Consumer (DTC) Genetic TestingFigure Manufacturing Cost Structure of Direct-To-Consumer (DTC) Genetic TestingFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Myriad Genetics ProfileTable Myriad Genetics Production, Value, Price, Gross Margin 2015-2020Table MD Revolution ProfileTable MD Revolution Production, Value, Price, Gross Margin 2015-2020Table DeCODEme ProfileTable DeCODEme Production, Value, Price, Gross Margin 2015-2020Table 23andMe ProfileTable 23andMe Production, Value, Price, Gross Margin 2015-2020Table Genetrainer ProfileTable Genetrainer Production, Value, Price, Gross Margin 2015-2020Table GeneByGene ProfileTable GeneByGene Production, Value, Price, Gross Margin 2015-2020Table DNA DTC ProfileTable DNA DTC Production, Value, Price, Gross Margin 2015-2020Table Genecodebook Oy ProfileTable Genecodebook Oy Production, Value, Price, Gross Margin 2015-2020Table Navigenics ProfileTable Navigenics Production, Value, Price, Gross Margin 2015-2020Figure Global Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Global Direct-To-Consumer (DTC) Genetic Testing Revenue ($) and Growth (2015-2020)Table Global Direct-To-Consumer (DTC) Genetic Testing Sales by Regions (2015-2020)Table Global Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Regions (2015-2020)Table Global Direct-To-Consumer (DTC) Genetic Testing Revenue ($) by Regions (2015-2020)Table Global Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Regions (2015-2020)Table Global Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Regions in 2015Table Global Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Regions in 2019Figure North America Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Europe Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Middle East and Africa Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure South America Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure North America Direct-To-Consumer (DTC) Genetic Testing Revenue ($) and Growth (2015-2020)Table North America Direct-To-Consumer (DTC) Genetic Testing Sales by Countries (2015-2020)Table North America Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Countries (2015-2020)Figure North America Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Countries in 2015Figure North America Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Countries in 2019Table North America Direct-To-Consumer (DTC) Genetic Testing Revenue ($) by Countries (2015-2020)Table North America Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Countries (2015-2020)Figure North America Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Countries in 2015Figure North America Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Countries in 2019Figure United States Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Canada Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Mexico Direct-To-Consumer (DTC) Genetic Testing Sales and Growth (2015-2020)Figure Europe Direct-To-Consumer (DTC) Genetic Testing Revenue ($) Growth (2015-2020)Table Europe Direct-To-Consumer (DTC) Genetic Testing Sales by Countries (2015-2020)Table Europe Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Countries (2015-2020)Figure Europe Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Countries in 2015Figure Europe Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Countries in 2019Table Europe Direct-To-Consumer (DTC) Genetic Testing Revenue ($) by Countries (2015-2020)Table Europe Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Countries (2015-2020)Figure Europe Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Countries in 2015Figure Europe Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Countries in 2019Figure Germany Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure UK Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure France Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Italy Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Spain Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Russia Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Revenue ($) and Growth (2015-2020)Table Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Sales by Countries (2015-2020)Table Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Countries in 2015Figure Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Sales Market Share by Countries in 2019Table Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Revenue ($) by Countries (2015-2020)Table Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Countries in 2015Figure Asia-Pacific Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Countries in 2019Figure China Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Japan Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure South Korea Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Australia Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure India Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Southeast Asia Direct-To-Consumer (DTC) Genetic Testing Sales and Growth Rate (2015-2020)Figure Middle East and Africa Direct-To-Consumer (DTC) Genetic Testing Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read the rest here:
Analyzing Impacts of Covid-19 on Direct-To-Consumer (DTC) Genetic Testing Market Effects, Aftermath and Forecast To 2026 - Owned

Recommendation and review posted by Bethany Smith

As the government considers plans to carry out mass coronavirus testing, Sky News looks at the different types of tests available.

There are two different strands of testing - one is to find out if a person currently has COVID-19 and the other determines if they have had it and have built up antibodies.

PCR testing and antigen testing (often confused as the same kind of test) are different methods of testing, but both ascertain whether a person has COVID-19 at the time.

PCR testing

Polymerase chain reaction (PCR) testing is currently the most common form of testing in the UK and is seen as fairly reliable.

A swab is used to collect an RNA sample (the nucleic acid that converts DNA into proteins) from the patient's tonsils and inside their nose.

RNA is collected as it carries the genetic information of this specific virus.

This is then sent to a laboratory where the sample is heated and cooled so it multiplies into larger quantities of DNA.

Bioscientists can then see whether the SARS-CoV-2 virus (the virus that causes COVID-19) is present.

Because of the process, PCR tests are taking about two days and are currently only available to people with symptoms, those in households with symptoms, and key workers.

90-minute PCR test

Machines that can deliver on-the-spot genetic testing are being used to collect RNA for PCR testing, which can also detect the common flu.

The RNA, taken using swab samples placed into a cartridge, is inserted into the machine which carries out a PCR test and then identifies if the virus is present.

A successful pilot test across eight London hospitals using British start-up DnaNudge's machines is being rolled out to NHS hospitals, with the plan to deliver 5.8m tests in the next few months.

20-minute saliva test

Loop-mediated Isothermal Amplification (LAMP) is a similar process to PCR testing but produces many more viral RNA copies at a constant temperature instead of heating and cooling.

A swab is used to take samples from the nose or throat, or mucus from hard coughing can also be used.

The samples are then placed in vials of reagents (substances that produce a chemical reaction to detect the RNA), then heated in a special machine for 20 minutes.

The machine then analyses the sample and confirms if there is any SARS-CoV-1 RNA.

Health Secretary Matt Hancock announced on 3 September that the LAMP test would be part of a 500m funding boost after a successful pilot across Hampshire hospitals, GP test hubs and care homes.

No-swab saliva test

Patients can do this test at home by collecting about two millimetres of saliva into a sample pot, then sending it off to a laboratory.

The sample gets tested using LAMP technology in a lab and the result is then texted to the person.

It still takes about 48 hours but there is no need for a patient to leave their home or stick a swab down their throat or up their nose.

A government-funded trial in Southampton has been expanded from GPs to the city's university staff and students, and four schools.

Antigen testing

These tests look for antigens - proteins that are produced by the body when it recognises a foreign structure, such as the COVID-19 virus.

Antigens can easily be detected in saliva and laboratory testing is not necessary, so can be done in places such as care homes and without a medical professional.

Results can be provided more quickly than PCR tests, with some systems already available and dozens more being developed.

20-second test

Released this week, the Virolens system uses a portable machine which creates a microscopic holographic image to detect the virus in saliva samples in 20 seconds.

Developed by British companies iAbra and TT Electronics, it uses a digital camera attached to a microscope, which then runs data through a computer that can identify the virus from other cells.

The device has been trialled at Heathrow Airport, whose chief executive, John Holland-Kaye, has urged the government to fast-track the technology to be used across the UK.

Antibody testing

Not currently available to the general public on the NHS, antibody testing looks at whether your body has produced any antibodies to fight against the virus.

A blood test is taken from a person who has had COVID-19 symptoms that have disappeared three to four weeks before.

A lab test then takes a unique protein the virus makes and tests whether any antibodies in the blood bind to that protein.

There are pin-prick tests in development which would allow a person to submit their own blood test, but these have not been rolled out yet.

:: Subscribe to the Daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker

Unlike other diseases, the UK government and the World Health Organisation agree there is currently no evidence that someone with antibodies will not catch COVID-19 again in the future.

This is why the government has not rolled antibody testing out to the general public, although tests are available privately.

NHS staff, care staff and some people in care homes and in hospital are having antibody tests.

Visit link:
Coronavirus: What are the different types of COVID-19 tests? - Sky News

Recommendation and review posted by Bethany Smith

This Breast Cancer Predictive Genetic Testing Market report 2020 delivers in-depth impression, describing about the Product/Industry Scope and expands market insights and forecast to 2024. It shows market data by industry drivers, restraints and opportunity, also analyses the market status, industry share, size, future trends and growth rate of market. Breast Cancer Predictive Genetic Testing market report is categorized based application, end-user, technology, the types of product/service, and others, as well as regions. Additionally, the report comprehends the calculated expected CAGR of the Breast Cancer Predictive Genetic Testing market derivative from previous records about the Breast Cancer Predictive Genetic Testing market and current market trends organized with future developments.

Final Report will add the analysis of the impact of COVID-19 on this industry.

Request a sample copy of the reporthttps://www.industryresearch.biz/enquiry/request-sample/13935123

The report mainly studies the Breast Cancer Predictive Genetic Testing market size, recent trends and development status, as well as investment opportunities, market dynamics (such as driving factors, restraining factors), and industry news (like mergers, acquisitions, and investments). Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Breast Cancer Predictive Genetic Testing market.

Key players in the global Breast Cancer Predictive Genetic Testing market covered in Chapter 4:

Global Breast Cancer Predictive Genetic Testing Industry 2020 Market Research Report also provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

To Understand How Covid-19 Impact Is Covered in This Report https://www.industryresearch.biz/enquiry/request-covid19/13935123

Scope of the Breast Cancer Predictive Genetic Testing Market Report:

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2024) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

Enquire before purchasing this reporthttps://www.industryresearch.biz/enquiry/pre-order-enquiry/13935123

Most important Types of Breast Cancer Predictive Genetic Testing products covered in this report are:

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including:

Global Breast Cancer Predictive Genetic Testing Market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. The Global Breast Cancer Predictive Genetic Testing market development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Some of the key questions answered in this report:

Purchase this report (Price 2960 USD for a single-user license)https://www.industryresearch.biz/purchase/13935123

There are 13 Chapters to thoroughly display the Video Smoke Detection market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

Chapter 1: Video Smoke Detection Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Video Smoke Detection Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Video Smoke Detection.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Video Smoke Detection.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Video Smoke Detection by Regions (2014-2019).

Chapter 6: Video Smoke Detection Production, Consumption, Export and Import by Regions (2014-2019).

Chapter 7: Video Smoke Detection Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Video Smoke Detection.

Chapter 9: Video Smoke Detection Market Analysis and Forecast by Type and Application (2019-2024).

Chapter 10: Market Analysis and Forecast by Regions (2019-2024).

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

Detailed TOC of Global Breast Cancer Predictive Genetic Testing Market@https://www.industryresearch.biz/TOC/13935123

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.Industry Researchis the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Info:

Name: Mr. Ajay More

E-mail:[emailprotected]

Organization: Industry Research Biz

Phone:US +1424 253 0807 / UK +44 203 239 8187

Our Other Reports:

Passenger Service System Market 2020 Business Growth Analysis with COVID-19 Impact, Industry Size, Share, Future Demands, Emerging Trends, Development and Forecast till 2026

Beverage Stabilizers Market is Booming Globally with Top Players 2020: Global Current and Future Plans, Future Growth, Regional Trend, Leading Players Updates, Industry Demand by Forecast to 2026

Artwork Online Auctions Software Market Size 2020 Global Industry Trends, Future Growth, Regional Overview, Market Share, Revenue, and Forecast Outlook till 2026, Says Industry Research Biz

Global Aircraft Wire and Cable Market Size, Share, 2020 Movements by Key Findings, Covid-19 Impact Analysis, Progression Status, Revenue Expectation to 2026 Research Report by Industry Research Biz

Organic Cocoa Market 2020 Key Manufacturers, Size, Industry Share, Investment Opportunities, Future Trends, Market Impact, Revenue, Demand and Analysis by Forecast 2024

Global Intelligent Power Module (IPM) Market Size 2020 Industry Share, CAGR of 6.9%, Growth, Business Challenges, Investment Opportunities, Covid-19 Impact Analysis, Key Manufacturers and 2026 Forecast Research Report

Global Vitamins and Supplements Market Size, Share, 2020 Movements by Development Analysis, Progression Status, Revenue Expectation to 2025, Research Report by Industry Research Biz

Read the original here:
Breast Cancer Predictive Genetic Testing Market Growth Insight, Size, Industry Trends, Share, Emerging Technologies, Share, Competitive, Regional, And...

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has completed a Type C written response only meeting with the Office of Tissues and Advanced Therapies (OTAT), part of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), to obtain OTATs concurrence on the commencement of its next clinical trial for SRP-9001 using commercial process material. SRP-9001 (AAVrh74.MHCK7.micro-dystrophin) is Sareptas investigational gene transfer therapy for the treatment of Duchenne muscular dystrophy.

Among other items, OTAT has requested that Sarepta utilize an additional potency assay for release of SRP-9001 commercial process material prior to dosing in a clinical study. Sarepta has several existing assays and data that it believes could be employed in response to OTATs request. However, additional dialogue with the Agency is required to determine the acceptability of the potency assay approach.

We look forward to working with OTAT to potentially satisfy their requests and to obtain clarity on the timing of the commencement of our commercial supply study. We will provide further updates as we are able, said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. Every day, thousands of children degenerate from the irreversible damage caused by Duchenne muscular dystrophy. It is for that reason that we will work relentlessly with the Division to satisfy any requests of OTAT and continue the advancement of a potentially transformative therapy for these patients.

About SRP-9001 (AAVrh74.MHCK7.micro-dystrophin)SRP-9001 is an investigational gene transfer therapy intended to deliver the micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. Sarepta is responsible for global development and manufacturing for SRP-9001 and plans to commercialize SRP-9001 in the United States. In December 2019, the Company announced a licensing agreement granting Roche the exclusive right to launch and commercialize SRP-9001 outside the United States. Sarepta has exclusive rights to the micro-dystrophin gene therapy program initially developed at the Abigail Wexner Research Institute at Nationwide Childrens Hospital.

AboutSarepta TherapeuticsAt Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Sarepta Forward-Looking Statements

This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding Sareptas belief that its existing assays and data could be employed in response to OTATs request; the acceptability of Sareptas potency assay approach by the FDA; our plan to work with OTAT to potentially satisfy their requests and to obtain clarity on the timing of the commencement of our commercial supply study; and the potential of SRP-9001 to be a transformative therapy for DMD patients.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sareptas control. Known risk factors include, among others: delays in the commencement of Sareptas next clinical study for SRP-9001 could delay, prevent or limit our ability to gain regulatory approval for SRP-9001; any inability to complete successfully clinical development could result in additional costs to Sarepta or impair Sareptas ability to generate revenues from product sales, regulatory and commercialization milestones and royalties; SRP-9001 may not result in a viable treatment suitable for commercialization due to a variety of reasons, including the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; Sarepta may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its product candidates to market, due to a variety of reasons, many of which may be outside of Sareptas control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sareptas product candidates and the COVID-19 pandemic; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect Sareptas business, results of operations and the trading price of Sareptas common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors:Ian Estepan, 617-274-4052iestepan@sarepta.com

Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

See original here:
Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy -...

Recommendation and review posted by Bethany Smith

In nearly 40 years of the HIV epidemic, only two people have likely been cured of the virus. Both scenarios resulted from stem cell transplants needed to fight blood cancers such as leukemia. Inspired by these two cases, a team of scientists is studying a multipronged way to potentially control HIV without medication. It involves two different genetic alterations of immune cells and with a safer method of stem cell transplants, also referred to as bone marrow transplants, a procedure that is generally toxic and dangerous.

The research is being funded by a five-year $14.6 million grant from the National Institutes of Health. The scientists coleading the preclinical studies are Paula Cannon, PhD, a distinguished professor of molecular microbiology and immunology at the Keck School of Medicine of the University of Southern California, and Hans-Peter Kiem, MD, PhD, who directs the stem cell and gene therapy program at the Fred Hutchinson Cancer Research Center, also known as Fred Hutch. According to a Keck School of Medicine press release, the two other main partners are David Scadden, MD, a bone marrow transplant specialist and professor at Harvard University and the Harvard Stem Cell Institute, and the biotechnology company Magenta Therapeutics.

In the HIV cure scenariosinvolving the so-called Berlin and London patientsboth men received stem cell transplants from donors with a natural genetic mutation that made them resistant to HIV. Specifically, their genes resulted in immune cells that lack CCR5 receptors on their surface (HIV latches onto these receptors to infect cells). Unfortunately, this method isnt viable for the nearly 38 million people worldwide living with HIV. Not only is it expensive, toxic and riskyit involves wiping out the patients immune system and replacing it with the new immune cellsbut it also requires matched donors who are CCR5 negative. According to the press release, about 1% of the population have this mutation.

With funding from this new grant, researchers hope to overcome these challenges in several ways. First, Cannon has already developed a gene-editing method to remove the CCR5 receptors from a patients own stem cells. She now hopes to further genetically engineer stem cells so they release antibodies that block HIV.

Our engineered cells will be good neighbors, Cannon said in the press release. They secrete these protective molecules so that other cells, even if they arent engineered to be CCR5 negative, have some chance of being protected.

Fred Hutchs Kiem will use CAR-T therapya new method of genetically modifying immune cells that is emerging out of cancer researchwith the goal of creating T cells that attack HIV-infected cells.

In addition, other scientists involved in the federal grant aim to develop less toxic methods of bone marrow transplantationfor example, by reducing the amount of chemotherapy required and speeding up the process of creating the new immune system.

The research finding could translate to other illnesses, such as cancer, sickle cell anemia and autoimmune disorders.

A home run would be that we completely cure people of HIV, Cannon said. What Id be fine with is the idea that somebody no longer needs to take anti-HIV drugs every day because their immune system is keeping the virus under control so that it no longer causes health problems and, importantly, they cant transmit it to anybody else.

For the latest on the cure cases, see Famed London Man Probably Cured of HIV from earlier this year. And in related news, see $14M Federal Grant to Research CAR-T Gene Therapy to Cure HIV.

Excerpt from:
$14.6M Grant to Explore a Therapy to Control HIV Without Meds - Cancer Health Treatment News

Recommendation and review posted by Bethany Smith

LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that biotech industry veteran Sean Bohen, M.D., Ph.D., has been appointed to the Gyroscope Board of Directors, effective immediately. Dr. Bohen will also serve as Chair of the Boards Research and Development Committee. Dr. Bohen brings more than 30 years of experience in the discovery and development of new medicines. Over the course of his career, he has made significant contributions to the early- and late-stage development of numerous FDA-approved drugs.

Sean brings a wealth of experience to our board in researching potential new medicines and successfully bringing them to patients in need. He also brings expertise and knowledge in helping companies build impressive R&D and commercial units side by side. We are excited to work with him as we advance Gyroscopes programmes, said Khurem Farooq, Chief Executive Officer.

Dr. Bohen currently serves on the board of directors of Altrubio, Inc. Previously, Dr. Bohen was the Chief Medical Officer and Executive Vice President, Global Medicines Development, AstraZeneca LP, where he was responsible for AstraZenecas worldwide product development and clinical programmes. Prior to joining AstraZeneca, he was Senior Vice President of Genentech Early Development (gRED), where he led preclinical and clinical development programmes to deliver pivotal trial-ready drug candidates to Genentechs late-stage development pipeline. During this time, he also served as a clinical instructor at the Stanford University School of Medicine. He received both his Ph.D. in Biochemistry and M.D. from the University of California, San Francisco, and has been board certified in Internal Medicine and Medical Oncology.

About Gyroscope: Vision for Life

Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing and delivering gene therapy beyond rare disease to treat a leading cause of blindness, dry age-related macular degeneration. Our lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and a Phase II clinical trial called EXPLORE.

Syncona Ltd, our lead investor, helped us create the only retinal gene therapy company to combine discovery, research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London with locations in Philadelphia and San Francisco, our mission is to preserve sight and fight the devastating impact of blindness. For more information visit: http://www.gyroscopetx.com and follow us on Twitter (@GyroscopeTx) and on LinkedIn.

Read more here:
Gyroscope Therapeutics Announces Appointment of Sean Bohen to the Board of Directors - Business Wire

Recommendation and review posted by Bethany Smith

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc.(Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment ofWilliam H. Carson, M.D., to its Board of Directors.

Bill knows how to drive the development of innovative treatments including drugs for a wide range of diseases that affect the brain from concept to commercialization, saidFrancois Nader, M.D., Non-Executive Chairman of Prevails Board of Directors. We are thrilled that he will bring that expertise to bear at Prevail as we continue to develop gene therapies for patients suffering from devastating neurodegenerative diseases, including Parkinsons disease, frontotemporal dementia and Gaucher disease.

Dr. Carson was most recently the President and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), leading the development and regulatory approvals of Otsukas global compounds including Abilify Maintena, Rexulti, Samsca and Jynarque. He also oversaw the approval of Abilify MyCite, the first FDA-approved digital medicine. Dr. Carson joined Otsuka as Vice President of the Princeton Aripiprazole Unit in 2002, establishing the companys presence there. Before joining Otsuka, he rose through the ranks in the CNS Research and Development department at Bristol-Myers Squibb. Prior to joining the pharmaceutical industry, Dr. Carson, a board-certified psychiatrist, was an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina.

Dr. Carson currently serves as Chairman of the Board of Directors of OPDC, and is also the Chairman of the Board of the Sozosei Foundation, a newly established Otsuka charitable organization with a main focus on decriminalization of mental illness. He is a Board Member of Excision Biotherapeutics and Trustee of the non-profit Internet2. He is Board Chair Emeritus of the Sphinx Organization, which advocates for parity and inclusion in the arts. Dr. Carson holds an A.B. Degree from Harvard College and a M.D. degree from Case Western Reserve University. He is a Distinguished Fellow of the American Psychiatric Association, the National Medical Association and the Executive Leadership Council. Dr. Carson was named to Savoy Magazines 2018 list of the Top 100 Most Influential Blacks in Corporate America.

Dr. Carson is an outstanding and important addition to our Board of Directors, said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail. I know that he will bring both deep medical expertise and compassion for patients to the role, as well as his stellar track record of advancing therapies through clinical development, FDA approval and commercialization.

I am honored to join Prevail at this exciting time for the company, said Dr. Carson. Prevails programs are moving forward quickly, and promising data are beginning to emerge. I am looking forward to helping the company continue to advance its mission of developing potentially disease-modifying treatments for patients with neurodegenerative disorders.

AboutPrevail Therapeutics

Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The Company is developing PR001 for patients with Parkinsons disease withGBA1mutations (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia withGRNmutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.

Prevail was founded by Dr.Asa Abeliovichin 2017, through a collaborative effort withThe Silverstein Foundationfor Parkinsons with GBA and OrbiMed, and is headquartered inNewYork, NY.

Forward-Looking Statements Related to Prevail

Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning Prevails ability to develop potentially disease-modifying treatments for patients with neurodegenerative disorders. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Prevails novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; initial data or other preliminary analyses or results of early clinical trials may not be predictive of final trial results or of the results of later clinical trials; Prevails gene therapy programs may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change; the fact that gene therapies are novel, complex and difficult to manufacture; and risks relating to the impact on Prevails business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in Prevails filings with theSecurities and Exchange Commission(SEC), including the Risk Factors section of the Companys Quarterly Report on Form 10-Q for the period endedJune 30, 2020, filed with theSEConAugust 11, 2020, and its other documents subsequently filed with or furnished to theSEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Prevail undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:Mary CarmichaelTenBridge Communicationsmary@tenbridgecommunications.com617-413-3543

Investor Contact:investors@prevailtherapeutics.com

Read more:
Prevail Therapeutics Announces Appointment of William H. Carson, MD, to Board of Directors - BioSpace

Recommendation and review posted by Bethany Smith

New Jersey, United States, The Gene Therapy Market report 2020 provides a detailed impression, describe the product industry scope and the market expanded insights and forecasts up to 2027. It shows market data according to industry drivers, restraints and opportunities, analyzes the market status, the industry share, size, future Trends and growth rate of the market. The Gene Therapy Market report is categorized by application, end user, technology, product / service types, and other, as well as by region. In addition, the report includes the calculated expected CAGR of chitosan acetate-market derivative from the earlier records of the Gene Therapy Market, and current market trends, which are organized with future developments.

Gene Therapy Market was valued at USD 3.69 Billion in 2019 and is projected to reach USD 24.78 Billion by 2027, growing at a CAGR of 26.9% from 2020 to 2027.

Gene Therapy Market, By Product

Viral Vectorso Adeno-associated virus vectorso Retroviral vectors Gammaretroviral vectors Lentiviral vectorso Other viral vectors (herpes simplex and adenoviral vectors) Non-viral Vectorso Oligonucleotideso Other non-viral vectors (plasmids and RNAi)

Gene Therapy Market, By Indication

Neurological Diseases Cancer Hepatological Diseases Duchenne Muscular Dystrophy Other Indications

Gene Therapy Market, By Delivery Method

Ex vivo In vivo

The report provides detailed coverage of the Gene Therapy Market, including structure, definitions, applications, and Industry Chain classifications. The Gene Therapy Market analysis is provided for the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunities and development status of key regions. Development policies and plans are discussed and manufacturing processes and cost structures analyzed. This report also includes information on import / export consumption, supply and demand, costs, industry share, policy, Price, Sales and gross margins.

Ask For Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=40223&utm_source=TDC&utm_medium=001

Gene Therapy Market forecast up to 2027, with information such as company profiles, product picture and specification, capacity production, price, cost, revenue, and contact information. Upstream raw materials and equipment as well as downstream demand analyses are also carried out. The Gene Therapy Market size, development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and general research results are offered.

The Gene Therapy Market was created on the basis of an in-depth market analysis with contributions from industry experts. The report covers the growth prospects in the coming years and the discussion of the main providers.

To understand how the effects of COVID-19 are addressed in this report. A sample copy of the report is available at https://www.verifiedmarketresearch.com/product/gene-therapy-market/?utm_source=TDC&utm_medium=001

Verified Market Researchis a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email:[emailprotected]

View post:
Gene Therapy Market is Thriving Worldwide 2020 | Trends, Growth and Profit Analysis, Forecast by 2027 - The Daily Chronicle

Recommendation and review posted by Bethany Smith

Global Coronavirus pandemic has impacted all industries across the globe, Gene Therapy for Age related Macular Degeneration market being no exception. As Global economy heads towards major recession post 2009 crisis, Cognitive Market Research has published a recent study which meticulously studies impact of this crisis on Global Gene Therapy for Age related Macular Degeneration market and suggests possible measures to curtail them. This press release is a snapshot of research study and further information can be gathered by accessing complete report. To Contact Research Advisor Mail us @ [emailprotected] or call us on +1-312-376-8303.

The research report on global Gene Therapy for Age related Macular Degeneration market as well as industry is a detailed study that provides detailed information of major key players, product types & applications/end-users; historical figures, region analysis, market drivers/opportunities & restraints forecast scenarios, strategic planning, and a precise section for the effect of Covid-19 on the market. Our research analysts intensively determine the significant outlook of the global Gene Therapy for Age related Macular Degeneration market study with regard to primary & secondary data and they have represented it in the form of graphs, pie charts, tables & other pictorial representations for better understanding.

Subretinal, Intravitreal, Unspecified are some of the key types of market. All the type segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2027. Based on the application segment, the global market can be classified into Monotherapy, Combination Therapy . The analysis of application segment will help to analyze the demand for market across different end-use industries.

Request Free Sample Copy of Gene Therapy for Age related Macular Degeneration Market Research [emailprotected] https://cognitivemarketresearch.com/medical-devicesconsumables/gene-therapy-for-age-related-macular-degeneration-market-report#download_report

Amid the COVID-19 pandemic, the industry is witnessing a major change in operations.Some of the key players include RetroSense Therapeutics, REGENXBIO, AGTC . key players are changing their recruitment practices to comply with the social distancing norms enforced across several regions to mitigate the risk of infection. Additionally, companies are emphasizing on using advanced recruiting solutions and digital assets to avoid in-person meetings. Advanced technologies and manufacturing process are expected to play a decisive role in influencing the competitiveness of the market players.

Regional Analysis for Gene Therapy for Age related Macular Degeneration Market:North America (United States, Canada)Europe (Germany, Spain, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, India, Australia, and South Korea)Latin America (Brazil, Mexico, etc.)The Middle East and Africa (GCC and South Africa)

Get A Free Sample of Gene Therapy for Age related Macular Degeneration Market Report: https://cognitivemarketresearch.com/medical-devicesconsumables/gene-therapy-for-age-related-macular-degeneration-market-report#download_report

NOTE: Whole world is experiencing the impact of Covid-19 pandemic due to its increasing spread hence, the report comprises of an up to date scenario of the Gene Therapy for Age related Macular Degeneration market report. Research analyst team of our company is understanding & reviewing the Covid19 Impact on Market and all the necessary areas of the market that have been altered due to the change caused by Covid19 impact. Get in touch with us for more precise/in-depth information of the Gene Therapy for Age related Macular Degeneration market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Gene Therapy for Age related Macular Degeneration Market Report 2020 (Coronavirus Impact Analysis on Gene Therapy for Age related Macular Degeneration Market)

At the end of May, many states began lifting lockdown restrictions and reopening in order to revive their economies, despite warnings that it was still too early. As a result, by mid-July, around 33 states were reporting higher rates of new cases compared to the previous week with only three states reporting declining rates. Due to this Covid-19 pandemic, there has been disruptions in the supply chain which have made end-use businesses realize destructive in the manufacturing and business process. During this lockdown period, the plastic packaging helps the products to have longer shelf life as the public would not be able to buy new replacements for the expired products because most of the production units are closed.

About Us:Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

Continue reading here:
Reasons Industries to Thrive Post-Pandemic! Gene Therapy for Age related Macular Degeneration Market Report xyz Answers it Analysis by Key Companies...

Recommendation and review posted by Bethany Smith

A 2016 decision to link the research labs at the University of Maryland College Park with those at the University of Maryland at Baltimore is paying dividends in the competition for federal COVID-19 research dollars, a top education official told a science advisory panel on Wednesday.

The decision was a spinoff of the University of Maryland Strategic Partnership Act, said Laurie Ellen Locasio, vice president for research at the two institutions.

Now well be ranked together by the [National Science Foundation] in the U.S. rankings of research universities and together this makes us [an] over $1 billion public research enterprise, she told the Maryland Life Sciences Advisory Board.

With a multi-billion dollar research powerhouse, the privately-funded Johns Hopkins University, also operating here, Maryland is unusually well-positioned, Locasio said.

Very few states in the country have the distinction of having two research universities with over a billion dollars in research spending per year. Weve really shown up as central to this pandemic.

Martin Rosendale, the CEO of the Maryland Tech Council, said there are so many therapeutics and vaccines in development that keeping up with them all is a daunting task.

Many firms adopted a drop everything approach when the scope of the coronavirus challenge started to become apparent, he said.

We just saw a lot of amazing thing happening here in Maryland so many companies were pivoting immediately to support the response to the pandemic, he said. They were basically dropping their other work and on their own dime spending their own money evaluating their technologies, their platforms, how they could apply them to COVID-19.

Many of the big players have grabbed global headlines for their work on a possible vaccine. But smaller companies are making potentially valuable strides as well, Commerce Secretary Kelly M. Schulz told the panel.

Other firms are working to develop COVID tests that are faster and more reliable.

The Tech Council formed the Maryland COVID-19 Coalition to bring companies together, to make sure they knew who each other were and begin a conversation, Rosendale said. Twenty-five firms were part of the coalitions first call; 40 were on the second.

Chris P. Austin, director of the National Center for Advancing Translation Sciences at NIH, told the panel that the federal government has pumped more than $20 billion into COVID research.

Of that, we know that over $3 billion is coming here to Maryland, Rosendale said. Thats a testament to the amazing vaccine and cell-and-gene therapy industries that have grown up here.

If foundation and other non-government funds are added to the public dollars, the number is well over $4 billion, he added.

To play off the capital regions strengths in biotech, a group of industry leaders in Maryland, Washington, D.C., and Virginia is organizing a pandemic and bio-defense center to help countries around the globe guard against future pandemics.

Because of the prominence of whats going on with COVID-19 development in our region especially within Maryland with vaccine, diagnostics, and therapeutic research we are sort of the epicenter in the world right now, said Richard A. Bendis, president and CEO of BioHealth Innovation, Inc. in Rockville.

People are starting to take notice.

Schulz said the Department of Commerce paused its planned marketing efforts in the spring to focus on the pandemic, but now is ready to gear back up again with an Innovation Uncovered campaign.

Were going back to where we wanted to be at the beginning of the year, which was to push the bio- and the life sciences worlds out, because we have heard from [company executives] that Maryland needs to be seen as a strong, tight ecosystem for this industry, she said.

[emailprotected]

Read the rest here:
Md. Labs Developing Vaccines and Therapeutics, Attracting Federal Dollars - Josh Kurtz

Recommendation and review posted by Bethany Smith

Good Growth Opportunities In Global Gene Therapy in Oncology Market: Distinguished Technology Development with Major Production Goals Analysis by 2029

According to the latest market analysis report Gene Therapy in Oncology Market in-depth study and complete information about the market size, market offers and market dynamics. Global Gene Therapy in Oncology Market provides different sections and sub-sections based on separation by type, application, key players, and end-user, segments, developments, topographical areas of this market. This extensive report also highlights key insights on the factors that drive the growth of the market as well as key challenges that are required to Gene Therapy in Oncology growth in the projection period. The report presents a full analysis of the key factors such as developments, trends, predictions, drivers, and business growth, developing trends, competitive landscape analysis. Development strategies and policies are presented as well as manufacturing processes and value structures are also examined presented in the analytical surveying report, besides the cost structures and production methods.

For Better Understanding, Download Sample PDF of Gene Therapy in Oncology Market Research Report @https://market.us/report/gene-therapy-in-oncology-market/request-sample

Global Gene Therapy in Oncology Market gives a comprehensive overview, the key features that are required to improve the growth of the market in the coming future. Gene Therapy in Oncology Market presenting information such as supply and demand situation, the competitive scenario, and the objections for market growth, market opportunities, and the threats faced by Top key players Bristol-Myers Squibb, Cold Genesys, Advantagene, Amgen, AstraZeneca, Bio-Path Holdings, CRISPR Therapeutics, Editas Medicine, Geron Corp, Idera Pharmaceuticals, Intellia Therapeutics, Johnson & Johnson, Marsala Biotech, Merck, . Many of the market players are interested in Gene Therapy in Oncology Market companies, raw material suppliers, machine suppliers, end users, traders, distributors. Building opportunities in this Gene Therapy in Oncology market and the growing progressions in the Gene Therapy in Oncology Market.It has been giving a clear understanding of primary and secondary research techniques and they are now intended towards collaborating accurate and exact data. The data gathered to structure this report is based on the data collection modules with large sample quantities.

The detailed segments and sub-segment of the market are explained below:

Top growing factors by Key Companies like:

Bristol-Myers Squibb, Advantagene, Amgen, Marsala Biotech, Idera Pharmaceuticals, Merck, Geron Corp, Intellia Therapeutics, , Editas Medicine, Johnson & Johnson, CRISPR Therapeutics, AstraZeneca, Cold Genesys and Bio-Path Holdings

Current Market Status, Trends, Types:

Ex Vivo, In Vivo

Review of Market Growth, Future Prospects, and Applications:

Hospitals, Diagnostics Centers, Research Institutes

Do Inquire AboutGene Therapy in OncologyMarket Report Here (Use Corporate email ID to Get Higher Priority):https://market.us/report/gene-therapy-in-oncology-market/#inquiry

Global Gene Therapy in Oncology Market: Regional Segmentation

1.North America (United States, Mexico, and Canada)

2.Europe (France, UK, Germany, Russia, and Italy)

3.Asia-Pacific (Korea, India, China, Japan, and Southeast Asia)

4.South America (Brazil, Argentina, Colombia, etc.)

5.Middle East and Africa (UAE, Egypt, Saudi Arabia, Nigeria, and South Africa)

Research Objectives Of Gene Therapy in Oncology Market Report:

A comprehensive overview of the market share and growth rate by type, application.

A complete analysis of the market opportunities, product scope, market risk, market driving force.

Analyze the top companies of Gene Therapy in Oncology Market Industry, with sales, revenue, and price

The report presents a forward-looking prospect on the global gene therapy in oncology market past data, status, and expected forecast, product, revenue, consumption.

It helps to recognize rising trends, drivers, growth influencing factors in global gene therapy in oncology market and regions.

It helps to prepare Marketing Policies by understanding the rising trends developing and improving gene therapy in oncology market development.

It supports to understand competitive developments such as developments, acquisitions, agreements, and new product launches in the gene therapy in oncology market.

*Please contact us for any specific customized requirements or changes you want and we will offer you the report as your requirement.

Browse Full Report withMore Professional and Technical insights including COVID-19 Impact:https://market.us/report/gene-therapy-in-oncology-market/

Why Go For Market.us Research?

Market.US specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons. We offer tactical and strategic support, which enables our esteemed clients to make well-informed business decisions and chart out future plans and attain success every single time. Besides analysis and scenarios, we provide insights into global, regional, and country-level information and data, to ensure nothing remains hidden in any target market. Our team of tried and tested individuals continues to break barriers in the field of market research as we forge forward with a new and ever-expanding focus on emerging markets.

Contact Us:

Mr. Benni JohnsonMarket.us (Powered By Prudour Pvt. Ltd.)Tel: +1 718 618 4351.Email:inquiry@market.us

Continued here:
Gene Therapy in Oncology Market Research Report By Application, Type, Key Players, Region and Forecast to 2029 - News Monitoring

Recommendation and review posted by Bethany Smith

TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer. The study is being conducted under a Cooperative Research and Development Agreement (CRADA) between the National Cancer Institute (NCI) and VBL.

Colon cancer is one of the most common cancers worldwide, but immune-based approaches in gastrointestinal cancers have unfortunately been largely unsuccessful, said Tim F. Greten, M.D., Deputy Branch Chief & Senior Investigator of the Thoracic and GI Malignancies Branch (TGMB), Co-Director of the NCI Center for Cancer Research (CCR) Liver Cancer Program, and the principal investigator of the study. The reasons for this are unclear, but no doubt relate to the fact that, in advanced disease, GI cancer appears to be less immunogenic. The goal of this Phase 2 study is to investigate whether priming with VB-111 followed by the addition of nivolumab may induce anti-tumor immune response in metastatic colorectal cancer, for which there remains a major unmet need.

We are pleased to see beginning of enrollment in this study, despite the challenges of COVID-19, said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. We look forward to collaborating with the NCI on investigating VB-111 for the potential benefit of patients with colorectal cancer.

For additional information on the study refer to https://clinicaltrials.gov/show/NCT04166383.

For patients interested in enrolling in this clinical study, please contact NCIs toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615) and/or the Web site: https://trials.cancer.gov

About VBLVascular Biogenics Ltd., operating asVBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBLs lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored all comers Phase 1 trial as well as in three VBL-sponsored tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.

Forward Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential, predict, project, should, will, would and similar expressions. These forward-looking statements include, but are not limited to, statements regarding our programs, including VB-111, including their clinical development, such as the timing of clinical trials and expected announcement of data, therapeutic potential and clinical results, and our financial position and cash runway. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, the impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines and clinical results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2019, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR CONTACT:

Michael RiceLifeSci Advisorsmrice@lifesciadvisors.com(646) 597-6979

Go here to see the original:
VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer - GlobeNewswire

Recommendation and review posted by Bethany Smith

Future technologies that could transform peoples lives such as high-performance batteries for electric vehicles, advanced medical treatments and robotics will receive a 65 million government cash boost today (Thursday 10 September).

The funding will be available through the governments Industrial Strategy Challenge Fund, which has been extended today to help develop solutions to some of the biggest global challenges, including climate change and tackling diseases such as cancer and Alzheimers.

Of the investment announced today:

nearly 44 million to develop the next generation of high-performance batteries for electric vehicles and wind turbines, which could also be used for new technologies such as electric aeroplanes. The funding will also be used to complete a first-of-its-kind UK Battery Industrialisation Centre, in Coventry, West Midlands, creating 100 high-skilled jobs. Organisations across the automotive, rail and aerospace sectors will have access a unique battery production facility combining manufacturing, experimentation and innovation

15 million to enable universities, research organisations and businesses to build robots to inspect, maintain and repair nuclear power stations, satellites and wind turbines. The robotics will also be used to address new problems resulting from the pandemic, including ones that can operated remotely and make contact-free deliveries or move hospital beds.

6.5 million will be allocated to the Advanced Therapy Treatment Centre network to accelerate patient access to advanced therapies through the development of specialised infrastructure for the delivery of these products in the NHS. These cell and gene based therapies are aimed at the treatment of life-limiting and inherited diseases such as cancer, Duchenne muscular dystrophy or cystic fibrosis.

Science Minister Amanda Solloway said:

We want to build back better by putting the UK at the forefront of new technologies to create high-skilled jobs, increase productivity and grow the economy as we recover from coronavirus.

This new funding will strengthen the UKs global status in a range of areas, including battery technologies for electric vehicles and robotics, helping us develop innovative solutions to some of our biggest global challenges and creating jobs in rewarding careers right across the country.

Challenge Director for The Faraday Battery Challenge Tony Harper said:

In order for batteries to play their full environmental and economic role in achieving Net Zero we need to deploy at scale and build supply chains for todays technology, shift from strong potential to commercial dominance in a new generation of batteries and continue to build world-class scientific capability to sustain us into the future. The announcement today confirms our commitment and determination to build on the hard-won progress the UK has made in the last 3 years on all these fronts and to accelerate progress post COVID-19.

CEO of the Cell and Gene Therapy Catapult Matthew Durdy said:

The ATTC network is a fantastic example of effective government intervention and the international community recognises this as part of the UKs leadership in the field. Bringing together companies, the NHS and regulatory bodies to make the use of cell and gene therapies easier, more cost effective, and more widespread both boosts the industry and brings these life changing medicines to patients who need them.

The fact that 12% of global clinical trials in cell and gene therapy take place in the UK and half of those involve ATTCs is a testament to the success of this highly respected programme.

Andrew Tyrer, Challenge Director for Robotics for a Safer World said:

I am delighted that the government has provided an extra 15 million funding to help academics and businesses bridge the gap to: complete on-going deliverables set against the Robots for a Safer World Challenge, and also; utilise knowledge gained to the benefit of new sectors, ahead of this Autumns spending review.

Established in 2017, the Industrial Strategy Challenge Fund is delivering 2.6 billion of government investment with the aim of funding world-leading research and highly innovative businesses to address the biggest industrial and societal challenges.

Todays announcement furthers the governments commitment through its R&D Roadmap to put the UK at the forefront of transformational technologies and is part of the governments wider commitment to increase R&D investment to 2.4% of GDP by 2027.

Excerpt from:
Government investment to help build robots for nuclear plants and batteries for electric aeroplanes - GOV.UK

Recommendation and review posted by Bethany Smith

Research

The worlds preeminent scientists say a theory from the Broad Institutes Alina Chan is too wild to be believed. But when the theory is about the possibility of COVID being man-made, is this science or censorship?

Illustration by Benjamen Purvis

In January, as she watched the news about a novel virus spreading out of control in China, Alina Chan braced for a shutdown. The molecular biologist at the Broad Institute of Harvard and MIT started stockpiling medicine and supplies. By the time March rolled around and a quarantine seemed imminent, shed bought hundreds of dollars worth of fillets from her favorite fishmonger in Cambridge and packed them into her freezer. Then she began to ramp down her projects in the lab, isolating her experimental cells from their cultures and freezing them in small tubes.

As prepared as she was for the shutdown, though, she found herself unprepared for the frustration of being frozen out of work. She paced the walls of her tiny apartment feeling bored and useless. Chan has been a puzzle demon since childhood, which was precisely what she loved about her workthe chance to solve fiendishly difficult problems about how viruses operate and how, through gene therapy, they could be repurposed to help cure devastating genetic diseases. Staring out her window at the eerily quiet streets of her Inman Square neighborhood, she groaned at the thought that it could be months before she was at it again. Her mind wandered back to 2003, when she was a teenager growing up in Singapore and the first SARS virus, a close relative of this coronavirus, appeared in Asia. It hadnt been anything like this. That one had been relatively easy to corral. How had this virus come out of nowhere and shut down the planet? Why was it so different? she asked herself.

Then it hit her: The worlds greatest puzzle was staring her in the face. Stuck at home, all she had to work with was her brain and her laptop. Maybe they were enough. Chan fired up the kettle for the first of what would become hundreds of cups of tea, stacked four boxes on her kitchen counter to raise her laptop to the proper height, pulled back her long dark hair, and began reading all of the scientific literature she could find on the coronavirus.

It wasnt long before she came across an article about the remarkable stability of the virus, whose genome had barely changed from the earliest human cases, despite trillions of replications. This perplexed Chan. Like many emerging infectious diseases, COVID-19 was thought to be zoonoticit originated in animals, then somehow found its way into people. At the time, the Chinese government and most scientists insisted the jump had happened at Wuhans seafood market, but that didnt make sense to Chan. If the virus had leapt from animals to humans in the market, it should have immediately started evolving to life inside its new human hosts. But it hadnt.

On a hunch, she decided to look at the literature on the 2003 SARS virus, which had jumped from civets to people. Bingo. A few papers mentioned its rapid evolution in its first months of existence. Chan felt the familiar surge of puzzle endorphins. The new virus really wasnt behaving like it should. Chan knew that delving further into this puzzle would require some deep genetic analysis, and she knew just the person for the task. She opened Google Chat and fired off a message to Shing Hei Zhan. He was an old friend from her days at the University of British Columbia and, more important, he was a computational god.

Do you want to partner on a very unusual paper? she wrote.

Sure, he replied.

One thing Chan noticed about the original SARS was that the virus in the first human cases was subtly differenta few dozen letters of genetic codefrom the one in the civets. That meant it had immediately morphed. She asked Zhan to pull up the genomes for the coronaviruses that had been found on surfaces in the Wuhan seafood market. Were they at all different from the earliest documented cases in humans?

Zhan ran the analysis. Nope, they were 100 percent the same. Definitely from humans, not animals. The seafood-market theory, which Chinese health officials and the World Health Organization espoused in the early days of the pandemic, was wrong. Chans puzzle detectors pulsed again. Shing, she messaged Zhan, this paper is going to be insane.

In the coming weeks, as the spring sun chased shadows across her kitchen floor, Chan stood at her counter and pounded out her paper, barely pausing to eat or sleep. It was clear that the first SARS evolved rapidly during its first three months of existence, constantly fine-tuning its ability to infect humans, and settling down only during the later stages of the epidemic. In contrast, the new virus looked a lot more like late-stage SARS. Its almost as if were missing the early phase, Chan marveled to Zhan. Or, as she put it in their paper, as if it was already well adapted for human transmission.

That was a profoundly provocative line. Chan was implying that the virus was already familiar with human physiology when it had its coming-out party in Wuhan in late 2019. If so, there were three possible explanations.

Perhaps it was just staggeringly bad luck: The mutations had all occurred in an earlier host species, and just happened to be the perfect genetic arrangement for an invasion of humanity. But that made no sense. Those mutations would have been disadvantageous in the old host.

Maybe the virus had been circulating undetected in humans for months, working out the kinks, and nobody had noticed. Also unlikely. Chinas health officials would not have missed it, and even if they had, theyd be able to go back now through stored samples to find the trail of earlier versions. And they werent coming up with anything.

That left a third possibility: The missing phase had happened in a lab, where the virus had been trained on human cells. Chan knew this was the third rail of potential explanations. At the time, conspiracy theorists were spinning bioweapon fantasies, and Chan was loath to give them any ammunition. But she also didnt want to play politics by withholding her findings. Chan is in her early thirties, still at the start of her career, and an absolute idealist about the purity of the scientific process. Facts were facts.

Or at least they used to be. Since the start of the pandemic, the Trump administration has been criticized for playing fast and loose with factsdenying, exaggerating, or spinning them to suit the presidents political needs. As a result, many scientists have learned to censor themselves for fear that their words will be misrepresented. Still, Chan thought, if she were to sit on scientific research just to avoid providing ammunition to conspiracy theorists or Trump, would she be any better than them?

Chan knew she had to move forward and make her findings public. In the final draft of her paper, she torpedoed the seafood-market theory, then laid out a case that the virus seemed curiously well adapted to humans. She mentioned all three possible explanations, carefully wording the third to emphasize that if the novel coronavirus did come from a lab, it would have been the result of an accident in the course of legitimate research.

On May 2, Chan uploaded the paper to a site where as-yet-unpublished biology papers known as preprints are shared for open peer review. She tweeted out the news and waited. On May 16, the Daily Mail, a British tabloid, picked up her research. The very next day, Newsweek ran a story with the headline Scientists Shouldnt Rule Out Lab as Source of Coronavirus, New Study Says.

And that, Chan says, is when shit exploded everywhere.

Alina Chan, a molecular biologist at the Broad Institute, says we cant rule out the possibility that the novel coronavirus originated in a labeven though she knows its a politically radioactive thing to say. / Photo by Mona Miri

Chan had come to my attention a week before the Newsweek story was published through her smart and straightforward tweets, which I found refreshing at a time when most scientists were avoiding any serious discussion about the possibility that COVID-19 had escaped from a biolab. Id written a lot about genetic engineering and so-called gain-of-function researchthe fascinating, if scary, line of science in which scientists alter viruses to make them more transmissible or lethal as a way of assessing how close those viruses are to causing pandemics. I also knew that deadly pathogens escape from biolabs with surprising frequency. Most of these accidents end up being harmless, but many researchers have been infected, and people have died as a result.

For years, concerned scientists have warned that this type of pathogen research was going to trigger a pandemic. Foremost among them was Harvard epidemiologist Marc Lipsitch, who founded the Cambridge Working Group in 2014 to lobby against these experiments. In a series of policy papers, op-eds, and scientific forums, he pointed out that accidents involving deadly pathogens occurred more than twice a week in U.S. labs, and estimated that just 10 labs performing gain-of-function research over a 10-year period would run a nearly 20 percent risk of an accidental release. In 2018, he argued that such a release could lead to global spread of a virulent virus, a biosafety incident on a scale never before seen.

Thanks in part to the Cambridge Working Group, the federal government briefly instituted a moratorium on such research. By 2017, however, the ban was lifted and U.S. labs were at it again. Today, in the United States and across the globe, there are dozens of labs conducting experiments on a daily basis with the deadliest known pathogens. One of them is the Wuhan Institute of Virology. For more than a decade, its scientists have been discovering coronaviruses in bats in southern China and bringing them back to their lab in Wuhan. There, they mix genes from different strains of these novel viruses to test their infectivity in human cells and lab animals.

When word spread in January that a novel coronavirus had caused an outbreak in Wuhanwhich is a thousand miles from where the bats that carry this lineage of viruses are naturally foundmany experts were quietly alarmed. There was no proof that the lab was the source of the virus, but the pieces fit.

Despite the evidence, the scientific community quickly dismissed the idea. Peter Daszak, president of EcoHealth Alliance, which has funded the work of the Wuhan Institute of Virology and other labs searching for new viruses, called the notion preposterous, and many other experts echoed that sentiment.

That wasnt necessarily what every scientist thought in private, though. They cant speak directly, one scientist told me confidentially, referring to the virology communitys fear of having their comments sensationalized in todays politically charged environment. Many virologists dont want to be hated by everyone in the field.

There are other potential reasons for the pushback. Theres long been a sense that if the public and politicians really knew about the dangerous pathogen research being conducted in many laboratories, theyd be outraged. Denying the possibility of a catastrophic incident like this, then, could be seen as a form of career preservation. For the substantial subset of virologists who perform gain-of-function research, Richard Ebright, a Rutgers microbiologist and another founding member of the Cambridge Working Group, told me, avoiding restrictions on research funding, avoiding implementation of appropriate biosafety standards, and avoiding implementation of appropriate research oversight are powerful motivators. Antonio Regalado, biomedicine editor of MIT Technology Review, put it more bluntly. If it turned out COVID-19 came from a lab, he tweeted, it would shatter the scientific edifice top to bottom.

Thats a pretty good incentive to simply dismiss the whole hypothesis, but it quickly amounted to a global gaslighting of the mediaand, by proxy, the public. An unhealthy absolutism set in: Either you insisted that any questions about lab involvement were absurd, or you were a tool of the Trump administration and its desperation to blame China for the virus. I was used to social media pundits ignoring inconvenient or politically toxic facts, but Id never expected to see that from some of our best scientists.

Which is why Chan stood out on Twitter, daring to speak truth to power. It is very difficult to do research when one hypothesis has been negatively cast as a conspiracy theory, she wrote. Then she offered some earnest advice to researchers, suggesting that most viral research should be done with neutered viruses that have had their replicating machinery removed in advance, so that even if they escaped confinement, they would be incapable of making copies of themselves. When these precautions are not followed, risk of lab escape is exponentially higher, she explained, adding, I hope the pandemic motivates local ethics and biosafety committees to think carefully about how they can reduce risk. She elaborated on this in another tweet several days later: Id alsopersonallyprefer if high biosafety level labs were not located in the most populous cities on earth.

How Safe Are Bostons Biolabs?

As one of the world centers of biotech, the Hub is peppered with academic and corporate labs doing research on pathogens. Foremost among them is Boston Universitys National Emerging Infectious Diseases Laboratories (NEIDL), the only lab in the city designated as BSL-4 (the highest level of biosafety and the same level as the Wuhan Institute of Virology). It is one of just a dozen or so in the United States equipped to work with live versions of the worlds most dangerous viruses, including Ebola and Marburg. Researchers there began doing so in 2018 after a decade of controversy: Many locals objected to the risks of siting such a facility in the center of a major metropolitan area.

The good news? Before opening, NEIDL undertook one of the most thorough risk assessments in history, learning from the mistakes of other facilities. Even Lynn Klotz, a senior science fellow at the Washington, DCbased Center for Arms Control and Non-Proliferation, who advised local groups that opposed NEIDL, told the medical website Contagion that the lab likely has the best possible security protocols and measures in place.

But the reality, Klotz added, is that most lab accidents are caused by human error, and there is only so much that can be done through good design and protocols to proactively prevent such mistakes. (Or to guard against an intentional release by a disgruntled researcher, as allegedly happened in the anthrax attacks of 2001.) Rutgers molecular biologist Richard Ebright, a longtime critic of potentially dangerous pathogen research, says the risks introduced by NEIDL are not low enough and definitely not worth the negligible benefits.

Still, risk is relative. Klotz has estimated the chance of a pathogen escape from a BSL-4 lab at 0.3 percent per year, and NEIDL is probably significantly safer than the typical BSL-4 lab. And if catching a deadly pathogen is your fear, well, currently you run a good risk of finding one in your own neighborhood. Until that gets cleared up, the citys biolabs are probably among the safer spaces in town.

Chan had started using her Twitter account this intensely only a few days earlier, as a form of outreach for her paper. The social platform has become the way many scientists find out about one anothers work, and studies have shown that attention on Twitter translates to increased citations for a paper in scientific literature. But its a famously raw forum. Many scientists are not prepared for the digital storms that roil the Twitterverse, and they dont handle it well. Chan dreaded it at first, but quickly took to Twitter like a digital native. Having Twitter elevates your work, she says. And I think its really fun to talk to nonscientists about that work.

After reading her tweets, I reviewed her preprint, which I found mind-blowing, and wrote her to say so. She thanked me and joked that she worried it might be career suicide.

It wasnt long before it began to look like she might be right.

Speaking her mind, it turns outeven in the face of censurewas nothing new for Chan, who is Canadian but was raised in Singapore, one of the more repressive regimes on earth. Her parents, both computer science professionals, encouraged free thinking and earnest inquiry in their daughter, but the local school system did not. Instead, it was a pressure-cooker of a system that rewarded students for falling in line, and moved quickly to silence rebels.

That was a bad fit for Chan. You have to bow to teachers, she says. Sometimes teachers from other classes would show up and ask me to bow to them. And I would say, No, youre not my teacher. Back then they believed in corporal punishment. A teacher could just take a big stick and beat you in front of the class. I got whacked so many times.

Still, Chan rebelled in small ways, skipping school and hanging out at the arcade. She also lost interest in her studies. I just really didnt like school. And I didnt like all the extracurriculars they pack you with in Singapore, she says. That changed when a teacher recruited her for math Olympiads, in which teams of students compete to solve devilishly hard arithmetic puzzles. I really loved it, she says. You just sit in a room and think about problems.

Chan might well have pursued a career in math, but then she came up against teams from China in Olympiad competitions. They would just wipe everyone else off the board, she says. They were machines. Theyd been trained in math since they could walk. Theyd hit the buzzer before you could even comprehend the question. I thought, Im not going to survive in this field.

Chan decided to pursue biology instead, studying at the University of British Columbia. I liked viruses from the time I was a teen, she says. I remember the first time I learned about HIV. I thought it was a puzzle and a challenge. That instinct took her to Harvard Medical School as a postdoc, where the puzzle became how to build virus-like biomolecules to accomplish tasks inside cells, and then to Ben Devermans lab at the Broad Institute. When I see an interesting question, I want to spend 100 percent of my time working on it, she says. I get really fixated on answering scientific questions.

Deverman, for his part, says he wasnt actively looking to expand his team when Chan came along, but when opportunities to hire extraordinary people fall in my lap, he takes them. Alina brings a ton of value to the lab, he explains, adding that she has an ability to pivot between different topics and cut to the chase. Nowhere was that more on display than with her coronavirus work, which Deverman was able to closely observe. In fact, Chan ran so many ideas past him that he eventually became a coauthor. She is insightful, determined, and has the rare ability to explain complex scientific findings to other scientists and to the public, he says.

Those skills would prove highly useful when word got out about her coronavirus paper.

If Chan had spent a lifetime learning how to pursue scientific questions, she spent most of the shutdown learning what happens when the answers you come up with are politically radioactive. After the Newsweek story ran, conservative-leaning publications seized on her paper as conclusive evidence that the virus had come from a lab. Everyone focused on the one line, Chan laments. The tabloids just zoomed in on it. Meanwhile, conspiracists took it as hard evidence of their wild theories that there had been an intentional leak.

Chan spent several exhausting days putting out online fires with the many people who had misconstrued her findings. I was so naive, she tells me with a quick, self-deprecating laugh. I just thought, Shouldnt the world be thinking about this fairly? I really have to kick myself now.

Even more troubling, though, were the reactions from other scientists. As soon as her paper got picked up by the media, luminaries in the field sought to censure her. Jonathan Eisen, a well-known professor at UC Davis, criticized the study in Newsweek and on his influential Twitter account, writing, Personally, I do not find the analysis in this new paper remotely convincing. In a long thread, he argued that comparing the new virus to SARS was not enough to show that it was preadapted to humans. He wanted to see comparisons to the initial leap of other viruses from animals to humans.

Moments later, Daszak piled on. The NIH had recently cut its grant to his organization, EcoHealth Alliance, after the Trump administration learned that some of it had gone to fund the Wuhan Institute of Virologys work. Daszak was working hard to get it restored and trying to stamp out any suggestion of a lab connection. He didnt hold back on Chan. This is sloppy research, he tweeted, calling it a poorly designed phylogenetic study with too many inferences and not enough data, riding on a wave of conspiracy to drive a higher impact. Peppering his tweets with exclamation points, he attacked the wording of the paper, arguing that one experiment it cited was impossible, and told Chan she didnt understand her own data. Afterward, a Daszak supporter followed up his thread with a GIF of a mike drop.

It was an old and familiar dynamic: threatened silverback male attempts to bully a junior female member of the tribe. As a postdoc, Chan was in a vulnerable position. The world of science is still a bit medieval in its power structure, with a handful of institutions and individuals deciding who gets published, who gets positions, who gets grants. Theres little room for rebels.

What happened next was neither old nor familiar: Chan didnt back down. Sorry to disrupt mike drop, she tweeted, providing a link to a paper in the prestigious journal Nature that does that exact experiment you thought was impossible. Politely but firmly, she justified each point Daszak had attacked, showing him his mistakes. In the end, Daszak was reduced to arguing that she had used the word isolate incorrectly. In a coup de grce, Chan pointed out that actually the word had come from online data provided by GenBank, the NIHs genetic sequence database. She offered to change it to whatever made sense. At that point, Daszak stopped replying. He insists, however, that Chan is overinterpreting her findings.

With Eisen, Chan readily agreed to test her hypothesis by finding other examples of viruses infecting new hosts. Within days, a perfect opportunity came along when news broke that the coronavirus had jumped from humans to minks at European fur farms. Sure enough, the mink version began to rapidly mutate. You actually see the rapid evolution happening, Chan said. Just in the first few weeks, the changes are quite drastic.

Chan also pointed out to Eisen that the whole goal of a website such as bioRxiv (pronounced bioarchive)where she posted the paperis to elicit feedback that will make papers better before publication. Good point, he replied. Eventually he conceded that there was a lot of interesting analysis in the paper and agreed to work with Chan on the next draft.

The Twitter duels with her powerful colleagues didnt rattle Chan. I thought Jonathan was very reasonable, she says. I really appreciated his expertise, even if he disagreed with me. I like that kind of feedback. It helped to make our paper better.

With Daszak, Chan is more circumspect. Some people have trouble keeping their emotions in check, she says. Whenever I saw his comments, Id just think, Is there something I can learn here? Is there something hes right about that I should be fixing? Ultimately, she decided, there was not.

By late May, both journalists and armchair detectives interested in the mystery of the coronavirus were discovering Chan as a kind of Holmes to our Watson. She crunched information at twice our speed, zeroing in on small details wed overlooked, and became a go-to for anyone looking for spin-free explications of the latest science on COVID-19. It was thrilling to see her reasoning in real time, a reminder of why Ive always loved science, with its pursuit of patterns that sometimes leads to exciting revelations. The website CNET featured her in a story about a league of scientists-turned-detectives who were using genetic sequencing technologies to uncover COVID-19s origins. After it came out, Chan added scientist-turned-detective to her Twitter bio.

Shes lived up to her new nom de tweet. As the search for the source of the virus continued, several scientific teams published papers identifying a closely related coronavirus in pangolinsanteater-like animals that are heavily trafficked in Asia for their meat and scales. The number of different studies made it seem as though this virus was ubiquitous in pangolins. Many scientists eagerly embraced the notion that the animals might have been the intermediate hosts that had passed the novel coronavirus to humans. It fit their preexisting theories about wet markets, and it would have meant no lab had been involved.

As Chan read the pangolin papers, she grew suspicious. The first one was by a team that had analyzed a group of the animals intercepted by anti-smuggling authorities in southern China. They found the closely related virus in a few of them, and published the genomes for that virus. Some of the other papers, though, were strangely ambiguous about where their data was coming from, or how their genomes had been constructed. Had they really taken samples from actual pangolins?

Once again, Chan messaged Shing Hei Zhan. Shing, somethings weird here, she wrote. Zhan pulled up the raw data from the papers and compared the genomes they had published. Individual copies of a virus coming from different animals should have small differences, just as individuals of a species have genetic differences. Yet the genomes in all of the pangolin papers were perfect matchesthe authors were all simply using the first groups data set. Far from being ubiquitous, the virus had been found only in a few pangolins who were held together, and it was unclear where they had caught it. The animals might have even caught it from their own smuggler.

Remarkably, one group of authors in Nature even appeared to use the same genetic sequences from the other paper as if it were confirmation of their own discovery. These sequences appear to be from the same virus (Pangolin-CoV) that we identified in the present study.

Chan called them out on Twitter: Of course its the same Pangolin-CoV, you used the same dataset! For context, she later added, Imagine if clinical trials were playing fast and loose with their patient data; renaming patients, throwing them into different datasets without clarification, possibly even describing the same patient multiple times across different studies unintentionally.

She and Zhan posted a new preprint on bioRxiv dismantling the pangolin papers. Confirmation came in June when the results of a study of hundreds of pangolins in the wildlife trade were announced: Not a single pangolin had any sign of a coronavirus. Chan took a victory lap on Twitter: Supports our hypothesis all this time. The pangolin theory collapsed.

Chan then turned her Holmesian powers on bigger game: Daszak and the Wuhan Institute of Virology. Daszak had been pleading his case everywhere from 60 Minutes to the New York Times and has been successful in rallying sympathy to his cause, even getting 77 Nobel laureates to sign a letter calling for the NIH to restore EcoHealth Alliances funding.

In several long and detailed tweetorials, Chan began to cast a cloud of suspicion on the WIVs work. She pointed out that scientists there had discovered a virus that is more than 96 percent identical to the COVID-19 coronavirus in 2013 in a mineshaft soon after three miners working there had died from a COVID-like illness. The WIV didnt share these findings until 2020, even though the goal of such work, Chan pointed out, was supposedly to identify viruses with the potential to cause human illnesses and warn the world about them.

Even though that virus had killed three miners, Daszak said it wasnt considered a priority to study at the time. We were looking for SARS-related virus, and this one was 20 percent different. We thought it was interesting, but not high risk. So we didnt do anything about it and put it in the freezer, he told a reporter from Wired. It was only in 2020, he maintained, that they started looking into it once they realized its similarity to COVID-19. But Chan pointed to an online database showing that the WIV had been genetically sequencing the mine virus in 2017 and 2018, analyzing it in a way they had done in the past with other viruses in preparation for running experiments with them. Diplomatic yet deadpan, she wrote, I think Daszak was misinformed.

For good measure, almost in passing, Chan pointed out a detail no one else had noticed: COVID-19 contains an uncommon genetic sequence that has been used by genetic engineers in the past to insert genes into coronaviruses without leaving a trace, and it falls at the exact point that would allow experimenters to swap out different genetic parts to change the infectivity. That same sequence can occur naturally in a coronavirus, so this was not irrefutable proof of an unnatural origin, Chan explained, only an observation. Still, it was enough for one Twitter user to muse, If capital punishment were as painful as what Alina Chan is doing to Daszak/WIV regarding their story, it would be illegal.

Daszak says that indeed he had been misinformed and was unaware that that virus found in the mine shaft had been sequenced before 2020. He also says that a great lab, with great scientists, is now being picked apart to search for suspicious behavior to support a preconceived theory. If you believe, deep down, something fishy went on, then what you do is you go through all the evidence and you try to look for things that support that belief, he says, adding, That is not how you find the truth.

Many of the points in Chans tweetorials had also been made by others, but she was the first reputable scientist to put it all together. That same week, Londons Sunday Times and the BBC ran stories following the same trail of breadcrumbs that Chan had laid out to suggest that there had been a coverup at the WIV. The story soon circulated around the world. In the meantime, the WIV has steadfastly denied any viral leak. Lab director Yanyi Wang went on Chinese television and described such charges as pure fabrication, and went on to explain that the bat coronavirus from 2013 was so different than COVID that it could not have evolved into it this quickly and that the lab only sequenced it and didnt obtain a live virus from it.

To this day, there is no definitive evidence as to whether the virus occurred naturally or had its origins in a lab, but the hypothesis that the Wuhan facility was the source is increasingly mainstream and the science behind it can no longer be ignored. And Chan is largely to thank for that.

In late spring, Chan walked through the tall glass doors of the Broad Institute for the first time in months. As she made her way across the gleaming marble foyer, her sneaker squeaks echoed in the silence. It was like the zombie apocalypse version of the Broad; all the bright lights but none of the people. It felt all the weirder that she was wearing her gym clothes to work.

A few days earlier, the Broad had begun letting researchers back into their labs to restart their projects. All computer work still needed to be done remotely, but bench scientists such as Chan could pop in just long enough to move along their cell cultures, provided they got tested for the virus every four days.

In her lab, Chan donned her white lab coat and took inventory, throwing out months of expired reagents and ordering new materials. Then she rescued a few samples from the freezer, took her seat at one of the tissue-culture hoodsstainless steel, air-controlled cabinets in which cell engineers do their workand began reviving some of her old experiments.

She had mixed emotions about being back. It felt good to free her gene-therapy projects from their stasis, and she was even more excited about the new project she and Deverman were working on: an online tool that allows vaccine developers to track changes in the viruss genome by time, location, and other characteristics. It came out of my personal frustration at not being able to get answers fast, she says.

On the other hand, she missed being all-consumed by her detective work. I wanted to stop after the pangolin preprint, she says, but this mystery keeps drawing me back in. So while she waits for her cell cultures to grow, shes been sleuthing on the sideonly this time she has more company: Increasingly, scientists have been quietly contacting her to share their own theories and papers about COVID-19s origins, forming something of a growing underground resistance. Theres a lot of curiosity, she says. People are starting to think more deeply about it. And they have to, she says, if we are going to prevent future outbreaks: Its really important to find out where this came from so it doesnt happen again.

That is what keeps Chan up at nightthe possibility of new outbreaks in humans from the same source. If the virus emerged naturally from a bat cave, there could well be other strains in existence ready to spill over. If they are closely related, whatever vaccines we develop might work on them, too. But that might not be the case with manipulated viruses from a laboratory. Someone could have been sampling viruses from different caves for a decade and just playing mix-and-match in the lab, and those viruses could be so different from one another that none of our vaccines will work on them, she says. Either way, We need to find where this came from, and close it down.

Whatever important information she finds, we can be sure Chan will share it with the world. Far from being shaken by the controversy her paper stirred, she is more committed than ever to holding a line that could all too easily be overrun. Scientists shouldnt be censoring themselves, she says. Were obliged to put all the data out there. We shouldnt be deciding that its better if the public doesnt know about this or that. If we start doing that, we lose credibility, and eventually we lose the publics trust. And thats not good for science. In fact, it would cause an epidemic of doubt, and that wouldnt be good for any of us.

Link:
Was COVID-19 Manmade? Meet the Scientist Behind the Theory - Boston magazine

Recommendation and review posted by Bethany Smith

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced thatNassim Usman, Ph.D., president and chief executive officer and Clinton Musil, chief financial officer ofCatalyst Biosciences, will participate in fireside chats at two investor conferences in September: The Morgan Stanley Global Healthcare Conference and the Cantor Virtual Global Healthcare Conference. Details for each can be found below.

An archived webcast of the presentations will be available for 90 days on theEvents and Presentationspage under the Investors section of the Companys website.

About Catalyst BiosciencesCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and complement-mediated disorders. Our protease engineering platform includes two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Our most advanced product candidate is marzeptacog alfa (activated) (MarzAA), a next-generation SQ FVIIa entering a Phase 3 registration study in late 2020. Our next late-stage product candidate is dalcinonacog alfa (DalcA), a next-generation SQ FIX, which has demonstrated efficacy and safety in a Phase 2b clinical trial in individuals with Hemophilia B. We have a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, that has demonstrated superiority compared with the Padua variant in preclinical models. Finally, we have a global license and collaboration agreement with Biogen for the development and commercialization of anti-complement Factor 3 (C3) pegylated CB 2782.

Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential benefits of products based on Catalysts engineered protease platform, plans to enroll the first patients in a Phase 3 registration study of MarzAA in late 2020, the potential for MarzAA and DalcA to effectively and therapeutically treat hemophilia subcutaneously, the superiority of CB 2679d-GT over other gene therapy, and the development of anti-complement Factor 3 (C3) pegylated CB 2782 by Biogen. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of the COVID-19 pandemic and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of DalcA or MarzAA, including the generation of neutralizing antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Companys products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalysts agreement, competition and other risks described in the Risk Factors section of the Companys quarterly report filed with the Securities and Exchange Commission on August 6, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:Ana KaporCatalyst Biosciences, Inc.investors@catbio.com

The rest is here:
Catalyst Biosciences to Participate in Two Upcoming Investor Conferences - GlobeNewswire

Recommendation and review posted by Bethany Smith

New York, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biologic Therapeutics Market 2020-2024" - https://www.reportlinker.com/p02448159/?utm_source=GNW Our reports on biologic therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the strong R&D pipeline, targeted therapeutic mechanism of biologics, and increasing investment in development of biologics. In addition, strong R&D pipeline is anticipated to boost the growth of the market as well. The biologic therapeutics market analysis includes product segment and geographical landscapes

The biologic therapeutics market is segmented as below: By Product Antibody therapeutics Vaccines Cell therapy Gene therapy Other therapies

By Geographic Landscapes North America Europe Asia ROW

This study identifies the introduction of biosimilars as one of the prime reasons driving the biologic therapeutics market growth during the next few years. Also, increasing incidence of chronic diseases and immunological disorders and patent expiry of major biologics will lead to sizable demand in the market.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our biologic therapeutics market covers the following areas: Biologic therapeutics market sizing Biologic therapeutics market forecast Biologic therapeutics market industry analysis

Read the full report: https://www.reportlinker.com/p02448159/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Excerpt from:
The Global Biologic Therapeutics Market is expected to grow by $ 190.94 bn during 2020-2024 progressing at a CAGR of 12% during the forecast period -...

Recommendation and review posted by Bethany Smith

The diabetes drug metforminderived from a lilac plant thats been used medicinally for more than a thousand yearshas been prescribed to hundreds of millions of people worldwide as the frontline treatment for type 2 diabetes. Yet scientists dont fully understand how the drug is so effective at controlling blood glucose.

Now, researchers at the Salk Institute say they have shown the importance of specific enzymes in the body for metformins function. In addition, the new work showed that the same proteins, regulated by metformin, controlled aspects of inflammation in mice, something the drug has not typically been prescribed for.

Apart from clarifying how metformin works, the research AMPK regulation of Raptor and TSC2 mediate Metformin effects on transcriptional control of anabolism and inflammation, which appears in Genes & Developmentreportedly has relevance for many other inflammatory diseases.

Despite being the frontline therapy for type 2 diabetes, the mechanisms of action of the biguanide drug metformin are still being discovered. In particular, the detailed molecular interplays between the AMPK and the mTORC1 pathway in the hepatic benefits of metformin are still ill-defined. Metformin-dependent activation of AMPK classically inhibits mTORC1 via TSC/RHEB. But several lines of evidence suggest additional mechanisms at play in metformin inhibition of mTORC1, write the investigators.

Here we investigated the role of direct AMPK-mediated serinephosphorylation of RAPTOR in a new RaptorAA mouse model, in which AMPK phospho-serine sites Ser722 and Ser792 of RAPTOR were mutated to alanine. Metformin treatment of primary hepatocytes and intact murine liver requires AMPK regulation of both RAPTOR and TSC2 to fully inhibit mTORC1, and this regulation is critical for both the translational and transcriptional response to metformin.

Transcriptionally, AMPK and mTORC1 were both important for regulation of anabolic metabolism and inflammatory programs triggered by metformin treatment. The hepatic transcriptional response in mice on high fat diet treated with metformin was largely ablated by AMPK-deficiency under the conditions examined, indicating the essential role of this kinase and its targets in metformin action in vivo.

These findings let us dig into precisely what metformin is doing at a molecular level, says Reuben Shaw, PhD, a professor in Salks Molecular and Cell Biology Laboratory and the senior author of the new paper. This more granular understanding of the drug is important because there is increasing interest in targeting these pathways for not only diabetes but immune diseases and cancer.

Researchers have known for 20 years that metformin activates a metabolic master switch, a protein called AMPK, which conserves a cells energy under low nutrient conditions, and which is activated naturally in the body following exercise. Twelve years ago, Shaw discovered that in healthy cells, AMPK starts a cascade effect, regulating two proteins called Raptor and TSC2, which results in a block of the central pro-growth protein complex called mTORC1 (mammalian target of rapamycin complex 1).

These findings helped explain the ability of metformin to inhibit the growth of tumor cells, an area of research that began to generate excitement after Shaw and others connected AMPK to a bona fide cancer gene in the early 2000s.

But in the intervening years, many additional proteins and pathways that metformin regulates have been discovered, drawing into question which of the targets of metformin are most important for different beneficial consequences of metformin treatment. Indeed, metformin is currently entering clinical trials in the United States as a general anti-aging treatment because it is effects are so well established from millions of patients and its side effects are minimal.

But whether AMPK or its targets Raptor or TSC2 are important for different effects of metformin remains poorly understood.

In the new work, in mice, Shaw and his colleagues genetically disconnected the master protein, AMPK, from the other proteins, so they could not receive signals from AMPK, but were able to otherwise function normally and receive input from other proteins.

When these mice were put on a high-fat diet triggering diabetes and then treated with metformin, the drug no longer had the same effects on liver cells as it did in normally diabetic animals, suggesting that communication between AMPK and mTORC1 is crucial for metformin to work.

By looking at genes regulated in the liver, the researchers found that when AMPK couldnt communicate with Raptor or TSC2, metformins effect on hundreds of genes was blocked. Some of these genes were related to lipid metabolism, helping explain some of metformins beneficial effects. But surprisingly, many others were linked to inflammation.

Metformin, the genetic data showed, normally turned on anti-inflammatory pathways and these effects required AMPK, TSC2 and Raptor.

We didnt go looking for a role in inflammation, so for it to come up so strongly was surprising, says Salk postdoctoral fellow and first author Jeanine Van Nostrand, PhD.

People suffering from obesity and diabetes often exhibit chronic inflammation, which further leads to additional weight gain and other maladies including heart disease and stroke. Therefore, identifying an important role for metformin and the interrelationship between AMPK and mTORC1 in control of both blood glucose and inflammation reveals how metformin can treat metabolic diseases by multiple means.

Metformin and exercise elicit similar beneficial outcomes, and research has previously shown that AMPK helps mediate some of the positive effects of exercise on the body, so among other questions, Shaw and Van Nostrand are interested in exploring whether Raptor and TSC2 are involved in the many beneficial effects of exercise, as well.

If turning on AMPK and shutting off mTORC1 are responsible for some of the systemic benefits of exercise, that means we might be able to better mimic this with new therapeutics designed to mimic some of those effects, says Shaw, who holds the William R. Brody Chair.

In the meantime, the new data suggest that researchers should study the potential use of metformin in inflammatory diseases, particular those involving liver inflammation. The findings also point toward AMPK, Raptor and TSC2 more broadly as potential targets in inflammatory conditions, suggesting the need for a deeper investigation of metformin, as well as newer AMPK agonists and mTOR inhibitors, the researchers say.

See more here:
Inflammation in the Liver Reversed by Metformin - Genetic Engineering & Biotechnology News

Recommendation and review posted by Bethany Smith

LONDON--(BUSINESS WIRE)--The global biologic therapeutics market size is expected to grow by USD 190.94 billion as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of 12%. Request Free Sample Report on COVID-19 Impacts

Read the 120-page report with TOC on "Biologic Therapeutics Market Analysis Report by Product (Antibody therapeutics, Vaccines, Cell therapy, Gene therapy, and Other therapies) and Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/biologic-therapeutics-market-industry-analysis

The market is driven by the strong R&D pipeline. In addition, the introduction of biosimilars is anticipated to boost the growth of the Biologic Therapeutics Market.

The efficiency of biologics in the treatment of severe infections, malignancies, and immunological and hormonal disorders is encouraging manufacturers to invest in R&D for the development of biologics. Monoclonal antibodies constitute one of the fastest growing segments amongst biological therapies. To date, 88 monoclonal antibodies have been approved for different indications. The pipeline of vendors such as AbbVie, Amgen, Johnson & Johnson, and F. Hoffmann-La Roche clearly indicates huge investments in R&D. Apart from manufacturers that are actively involved in research on biologics, many research institutes are also engaged in developing novel biologics through industrial collaborations. Thus, the strong R&D pipeline is expected to drive the biologic therapeutics market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Biologic Therapeutics Companies:

AbbVie Inc.

AbbVie Inc. operates in only one business segment that focuses on the discovery, development, manufacture, and commercialization of drugs for the treatment of various indications. The company's key offerings in the market include HUMIRA, CREON, and SURVANTA.

AstraZeneca Plc

AstraZeneca Plc generates revenue by developing and manufacturing pharmaceutical products. The company offers IMFINZI, which is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of PD-L 1 with the PD-1 and CD80 molecules.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co. operates in only one segment. This segment is responsible for the discovery, licensing, manufacture, marketing, distribution, and sales of medicines required to cure serious diseases. The company's key offerings include OPDIVO and YERVOY.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. has business operations under two segments: pharmaceuticals and diagnostics. The company offers atezolizumab, a monoclonal antibody, sold under the brand name TECENTRIQ for treating various cancers.

GlaxoSmithKline Plc

GlaxoSmithKline Plc operates its business through three segments: pharmaceuticals, consumer healthcare, and vaccines. The company's key offerings include NUCALA, BENLYSTA, and BEXXAR.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Biologic Therapeutics Market Product Outlook (Revenue, USD bn, 2020-2024)

Biologic Therapeutics Market Regional Outlook (Revenue, USD bn, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Link:
Global Biologic Therapeutics Market 2020-2024: COVID-19 Business Continuity Plan | Evolving Opportunities With AbbVie Inc. and AstraZeneca Plc |...

Recommendation and review posted by Bethany Smith

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in September 2020. The company will also host virtual one-on-one meetings during the conferences.

Details of the events are as follows:

Live webcasts of the presentation and fireside chats will be available on the Events page of the News & Media section of Fortresss website: http://www.fortressbiotech.com. Archived replays of the webcasts will be available for approximately 30 days following each presentation and fireside chat.

About Fortress BiotechFortress Biotech, Inc. (Fortress) is an innovative biopharmaceutical company that was recently ranked number 10 in Deloittes 2019 Technology Fast 500, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentage of fiscal year revenue growth over a three-year period. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the companys portfolio of product opportunities. Fortress has established partnerships with some of the worlds leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited), St. Jude Childrens Research Hospital and Nationwide Childrens Hospital. For more information, visit http://www.fortressbiotech.com.

Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words we, us and our may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees and consultants ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our Securities and Exchange Commission filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contacts:Jaclyn Jaffe and William BegienFortress Biotech, Inc.(781) 652-4500ir@fortressbiotech.com

Investor Relations Contact:Daniel FerryLifeSci Advisors, LLC(617) 430-7576daniel@lifesciadvisors.com

Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com

Originally posted here:
Fortress Biotech to Participate in Three September 2020 Virtual Investor Conferences - GlobeNewswire

Recommendation and review posted by Bethany Smith

New York, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p05965013/?utm_source=GNW By Application: Cancer, Infectious Disease, Neurology, Cardiovascular, Endocrinology, Gastroenterology and Other Applications By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World

Cross Segmentation

Applied Sciences: By Product, By Technology, By End User, By Region Precision Diagnostics: By Product, By Technology, By End User, By Region Precision Therapeutics: By Product, By Technology, By End User, By Region Digital Health and IT: By Product, By Technology, By End User, By Region

Regional Segmentation

North America: U.S. and Canada Europe: Germany, France, U.K., Italy, Spain, and Rest-of-Europe Asia-Pacific: Japan, China, India, Australia, and Rest-of-Asia-Pacific Latin America: Brazil, Mexico, and Rest-of-Latin America Rest-of-the-World

Growth Drivers

Advancement of Sequencing Technologies Rising Prevalence of Chronic Diseases Growing Demand for Preventive Care Shifting the Significance in Medicine from Reaction to Prevention Reducing Adverse Drug Reactions Through Pharmacogenomics Test Potential to Reduce the Overall Healthcare Cost Across the Globe

Market Challenges

Unified Framework for Data Integration Limited Knowledge about Molecular Mechanism/ Interaction Lack of Robust Reimbursement Landscape Regulatory Hurdles

Market Opportunities

Targeted Gene Therapy Expansion into the Emerging Markets Collaborations and Partnerships Across Value Chain to Accelerate the Market Entry

Key Companies Profiled

Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc., Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMrieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc., Intomics A/S, Johnson & Johnson Company, Konica Minolta, Inc., Laboratory Corporation of America, MDx Health, Inc., Menarini Silicon Biosystems, Inc., Merck KGaA, Myriad Genetics, Inc., Novartis AG, Oracle Corporation, Partek, Inc., Pfizer, Inc., QIAGEN N.V., Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi S.A., Sysmex Corporation, Teva Pharmaceuticals Industries Ltd., Thermo Fisher Scientific, Inc.

Key Questions Answered in this Report: What are the estimated and projected numbers for the global precision medicine market for 2020 and 2030? What are the drivers, challenges, and opportunities that are influencing the dynamics of the market? What is the competition layout of the market? What are the parameters on which competition mapping is carried out in the study? Which key development strategies are being followed and implemented by major players to help them sustain in the market? How are different segments of the market expected to perform during the forecast period from 2020 to 2030? The segments included in the comprehensive market study are: o product type o region o technology o application Which leading players are currently dominating the marke,t and what is the expected future scenario? Which companies are anticipated to be highly disruptive in the future, and why? How can the changing dynamics of the market impact the market share of different players operating in the market? What are the strategic recommendations offered in the study?

Market Overview

Precision medicine refers to the medicine developed as per an individuals genetic profile.It provides guidance regarding the prevention, diagnosis, and treatment of diseases.

The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.In the precision medicine market, the application of molecular biology is to study the cause of a patients disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patients health-related problems.

This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare, and increasing collaborations and agreements of IT firms with the diagnostics and biopharmaceutical companies for the development of precision diagnostic tools.

The current precision medicine market is mainly dominated by several majors, such as Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc, Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMrieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc. Intomics A/S, and Johnson & Johnson Company, Konica Minolta, Inc.

Within the research report, the market is segmented on the basis of product type, ecosystem application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide 360-degree coverage of the domain.

Competitive Landscape Major players, such as Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc, Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMrieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc., Intomics A/S, Johnson & Johnson Company, Konica Minolta, Inc., Laboratory Corporation of America MDx Health, Inc., Menarini Silicon Biosystems, Inc., Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG., Oracle Corporation, Partek, Inc., Pfizer, Inc., QIAGEN N.V., Quest Diagnostics Inc., Randox Laboratories Ltd., Sanofi SA, Sysmex Corporation, Teva Pharmaceuticals Industries Ltd., Thermo Fisher Scientific, Inc. including among others, led the number of key developments witnessed by the market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe. Countries Covered North America U.S. Canada Europe Germany France Spain U.K. Italy Rest-of-Europe Asia-Pacific Japan China India Australia Rest-of-Asia-Pacific (RoAPAC) Latin America Brazil Mexico Rest-of-Latin America (RoLA) Rest-of-the-World Israel Saudi Arabia United Arab Emirates South Africa RussiaRead the full report: https://www.reportlinker.com/p05965013/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Original post:
Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and...

Recommendation and review posted by Bethany Smith